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Abstract 
Mounting evidence suggests that two major vascular complications of diabetes 
mellitus, atherosclerosis and nephropathy, are pathogenically analogous 
processes, with atherosclerosis occurring primarily in the macrovasculature and 
nephropathy involving the microvasculature. Additionally, several lines of 
evidence point to oxidized low-density lipoprotein (oxLDL) as a major participant 
in both processes. OxLDL is found deposited in both types of vascular lesions, 
and appears to influence several events. It causes influx of macrophages, which 
ingest the oxLDL and are transformed into foam cells - a key component of 
atherosclerosis and glomerulosclerosis. OxLDL also appears to promote the 
proliferation of smooth muscle cells in atherosclerosis and mesangial cells in 
glomerulosclerosis; and expansion of the extracellular matrix in both lesions. 
Previous work in our laboratory has focused on the immunogenicity of oxLDL, 
and we have shown that heterogeneous LDL-containing immune complexes 
(LDL-IC), made with human LDL and rabbit LDL-hyperimmune antisera, are 
unmatched in their ability to drive the transformation of human monocyte-derived 
macrophages into foam cells. Recently, we undertook a three-part endeavor to 
better understand the pathogenic role of LDL-IC in microvascular and 
macrovascular complications of diabetes. Our goals were to 1) further 
characterize oxLDL antibodies that we isolated from serum and immune 
complexes; 2) considering the similarities between nephropathy and 
atherosclerosis, we wished to determine if LDL-IC are associated with diabetic 
nephropathy, as is observed in macrovascular disease; 3) detennine if artificially 
xi 
prepared homogeneous oxLDL-IC, made with oxLDL and human oxLDL 
antibodies, produce similar results in macro phages to those observed with the 
use of heterogeneous LDL-IC. 
Our characterization of oxLDLantibodies revealed that free and complexed 
antibodies, purified from serum and Ie were predominately of the IgG isotype, 
with IgG1 and IgG2 subclasses predominating. Interestingly, we found that the 
avidity of oxLDL antibodies isolated from ICs was significantly higher than that of 
free oxLDL antibodies. These findings suggest that oxLDL-ICs form stable 
circulating complexes and are composed of IgG subclasses that may render 
them pro-inflammatory. To investigate the potential association of LDL-IC with 
diabetic nephropathYf we compared the concentrations of free oxLDL antibodies, 
avidities of free and IC-bound oxLD antibodies, and concentrations of surrogate 
markers of LDL-ICs (lC-cholesterol and IC-apolipoprotein 8) in polyethylene 
glycol-precipitated les in three nephropathy classes of type 1 diabetic subjects. 
Subjects were classified according to their levels of urinary albuminuria, with the 
normoalbuminurics demonstrating a urinary albumin excretion (UAE) of 
<30mg/day; microalbuminurics had a UAE of 30-300mg/day; and 
macroalbuminurics had a UAE of greater than 300mg/day. We observed no 
significant difference in serum oxLDL antibody levels between groups, but 
identified a significant increase in IC-cholesterol and IC-apoliprotein B in the 
microalbuminuric and macroalbuminuric groups when compared to the 
normoalbuminuric group. Also, avidity levels of oxLDL isolated from immune 
complexes appeared to increase as nephropathy worsened. We interpreted 
xii 
these data to indicate a positive association between concentrations of LDL-ICs, 
and diabetic nephropathy, and that stable immune complexes formed with 
antibodies of higher affinity may playa role in the pathogenesis of renal disease 
in type 1 diabetes. Since these studies, in conjunction with our previous studies 
of heterogeneous LDL-IC-induced foam cell formation in human macrophages 
implicated LDL-IC as a potential participant in atherosclerosis and 
glomerulosclerosis, but required validation with homogeneous LDL-IC. To meet 
this objective, we purified human oxLDL antibodies and synthesized oxLDL-IC by 
mixing these antibodies with oxLDL. We then precipitated the oxLDL-IC using 
4% polyethylene glycol, and incubated the oxLDL-IC with THP-1 macrophages (a 
human monocyte-derived macrophage cell line). After 48 hours incubation, we 
extracted the cholesterol from these cells, and measured intracellular cholesterol 
ester accumulation. We observed intracellular cholesterol ester accumulation in 
cells incubated with oxLDL-IC that exceeded that of cells incubated with oxLDL 
alone, and these levels approached that observed in cells incubated with 
heterogeneous LDL-IC. These findings validate the continued use of 
heterogeneous LDL-IC in studies of foam cell formation. In conclusion, these 
findings demonstrate a positive association of diabetic microvascular disease 
and LDL-ICs that is reminiscent of that observed between LDL-IC and 
macrovascular dtsease. We have shown that homogeneous oxLDL-IC causes 
foam cell formation in macrophages, therefore are likely participants in 
microvascular (nephropathy) and macrovacular (atherosclerosis) diseases 
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processes. Lastly, we have validated the continued use of heterogeneous LDL-




Diabetes mellitus (OM-Attachment 1 ) has reached epidemic proportions in the 
developed nations of the world. This notoriously chronic debilitating disease is 
characterized by hyperglycemia and afflicts approximately 16 million people in 
the United States (ADA, 1998). All long-term diabetic complications are 
essentially the manifestation of diabetic vascular injury, encompassing both 
microvascular d~sease (nephropathy, retinopathy, and neuropathy) and 
macrovascular disease (atherosclerosis, ischaemic heart disease, 
cerebrovascular disease, and peripheral vascular disease) (Breyer, 1992; 
Cooper et aI., 1997; Kamanna et ai., 1997; Lloyd et ai., 1996; Lopes-Virella and 
Virella, 1998; Maser et aI., 1991; Nathan" 1993; Orchard et at., 1990; Raptis and 
Viberti, 2001);' with accelerated and aggressive atherosclerosis being the leading 
cause of morbidity and mortality in people with diabetes (Table 1). 
Although the pathogenesis of diabetes-related complications is poorly 
understood, the relationship between the development of diabetic complications 
and poorly controlled hyperglycemia is well established, and is associated with 
non-enzymatic glycosylation of proteins, especially collagen, hemoglobin, and 
lipoproteins (Brownlee et aI., 1984; Nathan, 1996). 
Table 1. Complications of diabetes in the United States (CDC, 1999; 
NCHS/CDC, 2000) 
Deaths 
- Diabetes is the direct cause of an estimated 65,000 deaths among 
Americans and is a contributing cause in another 95,000 deaths 
. anl')ually. 
Heart Disease and Stroke 
- People with diabetes have a two to four-fold increase in heart disease 
and are two to six times more likely to have a stroke than people who 
do not have diabetes. 
Kidney Disease 
- Diabetes is the single most common cause of end-stage renal 
disease (ESRO). 
- Thirty to forty percent of those with diabetes develop ESRD. 
- Currently over one-third of all patients with ESRD have diabetes and 
this number is expected to reach 50% if the current rate of increase 
continues. 
Blindness 
- Diabetes is the leading cause of blindness among adults 20 to 74 
years of age. 
Amputations 
- Diabetes is the underlying cause of the majority of lower limb 
amputations. 
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· Irrefutable evidence supporting this contention came from the nine-year Diabetes 
Control-and Complications Trial (DCeT) reported in 1993. In this large multi-
center study, rigid maintenance of near-normal glucose blood levels reduced the 
vascular complications of diabetes by more than 50% in 1441 subjects with type 
1 diabetes (DCCT/Research/Group, 1993). 
The Oxidant Stress Hypothesis 
Although compelling evidence points to glycation as a significant participant in 
the development of many complications of diabetes, the majority of researchers 
and clinicians in the field have well-founded doubts that it alone is directly 
responsible for diabetic complications because, quite simply, the structural 
changes observed in glycated tissues do not adequately explain all of the clinical 
observations (Wolff, 1987). It is widely accepted that the "missing link," in 
diabetes-related pathology is answered by a well-supported hypothesis that 
looks beyond glycation to one of its known effects: the oxidant stress hypothesis 
(Baynes, 1991; Hunt et aI., 1993; Hunt and Wolff, 1991; Miyata et aI., 1999; 
Salahudeen et aI., 1997; Wolff, 1987). This hypothesis may well be the missing 
piece of the diabetes puzzle, helping explain the diversity and severity of 
vascular complications. At the core of this hypothesis, glycation has been 
identified as the primary trigger for chronic complications of diabetes. 
Hyperglycemia leads to increased glycation of tissues, and a concomitant 
increased production of free radical reactive oxygen species (ROS). Being 
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chemically unstable moieties, free radicals are extremely reactive, interacting 
directly and indirectly with numerous macromolecules and tissues, causing 
oxidant stress-related pathogenesis (Baynes, 1991; Hunt et aI., 1993; Hunt and 
Wolff, 1991; Salahudeen at aI., 1997; Wolff, 1987)~ 
The proposed mechanism by which this takes place is as follows: when protein is 
exposed to glucose in vitro, glucose, like other alpha-hydroxyaldehydes, can 
enolize. Trace amounts of transition metals, iron and copper, then catalyze the 
conversion of the endiol to an endiol radical anion, which is oxidized to a 
ketoaldehyde. This "autoxidation" of glucose produces a steady flow of ROS that 
contribute to the oxidant stress insult. These free radicals are capable of 
causing significant structural and physiological damage by mediating the reaction 
of various glucose reactive products (Amadori adduct, etc.) with membrane 
proteins, as well as by oxidatively modifying numerous proteins (Baynes, 1991; 
Hunt et aI., 1993; Hunt and Wolff, 1991; Salahudeen et aI., 1997; Wolff, 1987) 
(Figure 1). 
Diabetic Vascular Complications and Low Density Lipoprotein (LDL) 
In diabetes research, LDL has received considerable, and well deserved, 
attention during the past decade. Not only is it increased in diabetes, but it is 
susceptible to glycation and oxidative modification; and its oxidized analog, 
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Figure 1. Substrate oxidation-derived damage. Substrates that can autoxidize, 
such as glucose, lead to the production of dicarbonyls and oxidants. Glucose 
oxidation is catalyzed by transition metals, such as copper, which are either free 
in solution or sequestered by protein. Copper attached to the protein may 
participate in glucose oxidation, and is involved in oxidative protein alterations 
involving hydrogen peroxide. The attachment of glucose to protein via the 
Amadori pathway is also shown (Hunt et aI., 1993; Hunt and Wolff, 1991). 
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macrovascular disease (Esterbauer et aI., 1992; Kreisberg, 1998; Steinberg, 
1993; Steinberg et aI., 1989). However, before discussing the potential 
pathogenic role of oxLDL in diabetes, it seems pertinent to first summarize some 
relevant properties of unmodified, o~ native, LDL (nLDL). 
By definition, human nLDL (Figure 2) is the population of lipoproteins that can be 
isolated by density-gradient ultracentrifugation within a range of 1.019 to 1.063 
g/mL. LDL functions in the blood as the primary supplier/carrier of free and 
esterified cholesterol to the peripheral tissues of the body (Olson, 1998). Its 
molecules are spherical particles of variable size, measuring 19-25 nM, with 
molecular masses of 1.8 to 2.8 million. Each LDL molecule consists of a 
hydrophobic lipid core containing 900/0 cholesteryl esters (CE) and 100/0 
triglycerides, surrounded by a phospholipid monolayer which contains a massive 
protein, apolipoprotein B (apoS) embedded in the outer layer (Myant, 1990). 
The biochemical composition of LDL is given in table 2. If one uses 2.5 
million as the mean molecular weight of LOL, each sphere is calculated to 
contain approximately 1600 molecules of CE and 170 molecules of triglycerides 
in the lipophilic core. Surrounding the oily core is a monolayer of approximately 
700 phospholipid molecules (primarily phosphatidylcholine with minute amounts 




cholesteryl esters (90% ) 
triglycerides (10% ) 
unesterified (free) 
cholesterol 
Figure 2. Schematic of a LDL particle. A hydrophobic lipid core consisting of 
relatively large quantities of cholesteryl esters (GE) and small quantities of 
triglycerides is surrounded a hydrophilic phospholipid monolayer, with a large 
protein moiety (apolipoprotein B) embedded. 
Table 2. Chemical composition of human LDL 
(Esterbauer et aI., 1992). 
Component mean (SO) 
Phospholipid (~mol/mg protein) 22.3 (3.0) 
Triglyceride (mg/mg protein) 5.6 (2.7) 
II Free cholesterol (mg/mg protein) 9.6 (0.7) II 





As expected, the polar heads of the phospholipids, which are positioned along 
the outermost periphery of the LDL particle, interface with water and enhance 
the solubility of LDL in the blood. Also, embedded in the phospholipid monolayer 
of LDL is apoS, the largest known single-chain protein, weighing an impressive 
550 kDa. Functions of apoB are multifaceted, with it enhancing aqueous 
solubility, and appearing to be involved in receptor-mediated endocytosis of LDL 
into, cells. Structurally, it is unlikely that apoB sits on the LDL molecule like a hat; 
rather experimental data suggest it embraces a large area of the phospholipid 
surface of LDL in an octopus-like manner (Esterbauer et aI., 1992). 
Extending the discussion of LDL beyond structure to include function, a brief 
review of normal intracellular cholesterol metabolism as described by Brown and 
Goldstein (Brown and Goldstein, 1984; Brown and Goldstein, 1986) is needed to 
help frame the questions addressed in this thesis. As illustrated in figure 3, 
intracellular cholesterol is generally derived from two sources: the exogenous 
(major) or LDL receptor (LDL-R) pathway, and the endogenous (minor) or 3-
hydroxy-3-methylglutaryl-coenzyme A (HMG CoAl reductase pathway. Under 
normal circumstances, intracellular levels of unesterified (free) cholesterol are 
under tight control and maintained within a very narrow range. As intracellular 
levels of free cholesterol increase, the following four effects serve as 
components of a negative feedback loop: 1) cholesterol is incorporated into the 
8 
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Figure 3. Normal cholesterol homeostasis in mammalian cells. LDL binds to its 
receptor and is ingested by receptor-mediated endocytosis, followed by 
internalization and vesicle formation. The vesicle then fuses with a compartment 
of uncoupling of receptor and ligand (CURL), where the LDL receptors are 
recycled to the cell's surface and LDL is delivered to a lysosome for degradation 
of apoB to its constituent amino acids along with cleavage of the esterified 
cholesterol to unesterified (free) cholesterol and fatty acids. Intracellular levels of 
unesterified cholesterol are normally tightly regulated. Abnormally high levels of 
intracellular cholesterol trigger intracellular metabolic events indicated by + 
(enhancing) or - (inhibiting). The bold outer lines of LDL indicate the protein 
moiety (apoB); the inner spheres indicate lipid. Modified from the description of 
Brown and Goldstein, published in 1979 (Brown and Goldstein, 1979). 
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3) cholesterol synthesis is curtailed by reducing the synthesis of HMG CoA 
reductase; and 4) the activity of acyl CoA:cholesterol acyltr~nsferase (ACAT) is 
increased, driving the synthesis of cholesterol esters for storage in the 
cytoplasm. These regulatory events are mediated by sterol regulatory element 
binding protein, which monitors the free cholesterol concentration in the cell and 
adjusts the expression of cholesterol regulatory genes (Chin and Chang, 1981; 
Mazzone et aI., 1988; Wang et aI., 1994). The inhibition of LDL receptor 
expression and HMG-CoA reductase, in conjunction with enhanced ACAT 
activity, effectively curtails internalization of LDL and de novo synthesis of 
cholesterol, while enhancing storage of cholesterol esters. 
Oxidation, LDL, and Diabetes 
Knowledge regarding the mechanisms of oxidation of LDL in vivo is incomplete; 
however, what follows is a summary of current thought regarding this process, 
and a description of some of the known products of LDL oxidation (Esterbauer et 
aI., 1991; Miyata et aI., 1999; Steinbrecher, 1987). Current dogma contends that 
oxidation of LDL requires a microenvironment within the arterial wall where LDL 
is trapped and sequestered from circulating antioxidants and where the levels of 
redox-active metal ions are increased (Lopes-Virella and Virella, 1994b). 
Modification may occur directly, as a result of the generation of ROS, followed by 
oxidation of amino acids contained within apoB, or indirectly by reactive carbonyl 
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Figure 4. Oxidation produces neoepitopes. Autoxidation of carbohydrates 
produces glyoxal and methylglyoxal-Iysine dimmers; Lipid peroxidation produces 
malondialdehyde (MDA) lysine and hydroxynonenal (HNE)-Iysine; oxidation of 
the hydroxyaminoacid, serine produces carboxymethyllysine (CML) - adapted 
from Miyata et al. (Miyata et aI., 1999). 
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acids (Miyata et aI., 1999) (Figure 4). Autoxidation of carbohydrates produces 
reactive carbonyl compounds, such as glyoxal (Wells-Knecht et aI., 1995) and 
methylglyoxal·(Ahmed et al., 1997). Lipid peroxidation of polyunsaturated fatty 
acids residing in phospholipids and CE in the lipoprotein core are prone to form 
highly reactive degradation products, of which, matondialdehyde (MDA) and 4-
hydroxynonenal (4-HNE)-modified lysine, tyrosine, arginine, and histidine are 
best described (Chen et aI., 1992; Esterbauer et aI., 1991; Palinski et aI., 1989). 
Oxidation of the hydroxyamino acid, L-serine produces a carbonyl compound 
highly reactive with proteins, leading to formation of carboxymethyllysine (CML) 
(Anderson et aI., 1997). Each of the reactive fragments described above may, in 
turn attach covalently to lysine and histidine residues of apaB, and in the case of 
MDAl4-HNE, form advanced lipoxidation end products (ALEs). In addition to the 
generation of LDL oxidation-induced adducts, free radical-induced damage of 
the protein component of LDL has been shown to cause fragmentation of apoB, 
with the fragments subsequently forming high molecular weight aggregates 
(Bellamy et aI., 1989) in vitro. In toto, a large variety of LDL neoepitopes are 
likely to be generated by these oxidation-induced processes. As noted earlier in 
this chapter, an overwhelming body of evidence exists suggesting that diabetes 
is associated with increased oxidant stress and enhanced lipid peroxidation 
(Baynes, 1991; Hunt et aI., 1993; Hunt and Wolff, 1991; Mooradian, 1991; Rabini 
et a I., 1994). 
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Following this line of evidence, oxidation of LDL can occur via one or more of 
several mechanisms, including: 1) Autoxidation of glucose or Amadori 
compounds generates ROS capable of oxidizing LDL (Azevedo et aI., 1988; 
Gillery et aL, 1988; Hunt et aI., 1993; Hunt et aI., 1990; Hunt and Wolff, 1991; 
Kawamura et aI., 1994; Mullarkey et aI., 1990; Wolff, 1987); 2) glycation of apoB 
may generate free radicals, thus initiating oxidation of the LDL particle (Wolff, 
1987); 3) nonenzymatic glycation may prolong the half-life of LDL circulating in 
the blood, which, in combination with trapping of glycated LDL in the vessel wall 
(due to covalent cross-linking to glycated structural proteins) increases the 
probability of oxidation (Brownlee et aI., 1984; Kortland et aI., 1992); 4) small, 
dense LDL particles are found in increased concentrations in poorly controlled 
diabetes, and are more easily oxidized than larger, less dense LDL particles 
found in non-diabetic control subjects and subjects with tightly controlled 
diabetes (de Graaf et aI., 1991; James and Pometta, 1990; James and Pometta, 
1991; Lahdenpera et aI., 1994; Tomkin and Owens, 1994); 5) increased plasma 
triglyceride levels, which are commonly observed in poorly controlled diabetes, 
are significantly correlated with increased susceptibility of LDL to oxidation in 
patients with atherosclerosis (Gin et aI., 2000; Kamanna et aI., 1997; Kreisberg, 
1998; Lopes-Virella et aI., 1983; Regenstrom et aI., 1991). 
Interestingly, discovery of ox~DL, along with a rapidly growing appreCiation of the 
major role post-translationally modified LDL seems to play in atherogenesis, 
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occurred during investigations of an apparent paradox. In a series of sentinel 
experiments aimed at characterizing the LDL receptor, Brown and -Goldstein 
(Brown and Goldstein, 1986; Brown and Goldstein, 1990) made an unexpected 
discovery. Their work demonstrated, for the first time, that virtually all cholesterol 
in a cell is derived from LOL, and that endocytosis of LDL is receptor-mediated. 
As they continued their investigations, they discovered that people who lack 
functional LDL receptors (familial hypercholesterolemia) develop atherosclerotic 
lesions that are indistinguishable from those found in people with fully functional 
LDL receptors. In searching for answers to this apparent. paradox, their elegant 
studies demonstrated that the risk of cardiovascular disease was not directly due 
to native LOL as many believed. Indeed, it is common knowledge that all cells 
require cholesterol supplied by LOL for a variety of functions to include steroid 
hormone production and membrane synthesis. However, the abnormal 
accumulation of LOL cholesterol in atherosclerotic plaques appeared to be 
heavily influenced by post-translational modification of LOL. They discovered 
that the accumulation of native LDL in the cytoplasm of cells is a tightly regulated 
process, with increasing levels of intracellular cholesterol triggering decreased 
expression 'of LDL receptors. However, post-translational modification . 
(acetylation and oxidation, for example) of LDL appeared to negate the stringent 
control exerted by the cells' surface LDL receptors, promoting unchecked entry 
via scavenger receptors. They observed that when monocyte-derived 
macrophages ingested native LOL, lipid-induced negative feedback caused 
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down regulation of LDL receptors, and prevented over-accumulation of LDL in 
the macrophages. However, when macrophages ingested modified LDL (Le. 
QxLDL), negative regulation appear~d to be bypassed, causing unregulated 
uptake of LDL and the resultant transformation of these macrophages into lipid-
laden foam cells (FCs) (Brow" and Goldstein, 1990). Adding to this paradox, 
Lopes-Virella et a/. discovered that human monocyte-derived macrophages 
incubated with oxLDL or LDL-containing immune complexes (LDL-IC) exhibited 
an unexpected up regulation of LDL receptors (Lopes-Virella et aI., 1991). 
Although these cells had extremely elevated levels of cholesterol, inexplicably 
they continued ingesting more lipoprotein than they could excrete, causing 
cholesterol to be stored in their cytoplasm in the form of cholesteryl ester 
droplets, ultimately transforming them into foam cells and causing cell death. 
Interestingly, during these experiments, observations were reported that are very 
germane to this dissertation, and will be discussed in more detail shortly: LDL-
containing immune complexes appeared to enhance foam cell formation more 
efficiently than modified LDL alone (Gisinger and Lopes-Vi rella, 1992; Griffith et 
aI., 1988; Lopes-Virella et aI., 1997a; Lopes-Virella et aI., 1991; Lopes-Virella et 
aI., 1997b; Lopes-Virella and Virella, 1992). 
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Table 3. Characteristics of OxLDL (Lopes-Virella and Virella, 1996; 
Schwartz et aI., 1991; Steinberg, 1993) 
- Chemotactic for monocytes, T lymphocytes 
- Expands extracellular matrix 
- Phagocytized by macrophages, causes foam cell transformation 
- Cytotoxic 
Enhances. leukocyte adhesion to the endothelium 
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Modified LDL and LDL-IC are Involved in Complications of Diabetes 
Research during the past decade has produced compelling evidence that two 
major complications of diabetes, atherosclerosis (primarily a macrovascular 
disease) and glomerulosclerosis (primarily a microvascular disease), share some 
pathogenic elements; and that oxLDL (Table 3) plays a significant role in both 
processes (Diamond, 1991; Hunt et aI., 1993; Hunt and Wolff, 1991; Kamanna et 
aI., 1997; Magil, 1999; Moorhead et aI., 1997; Salahudeen et aI., 1997; Witztum, 
1994a). 
Although atherosclerosis is generally considered a macrovascular disease and 
glomerulosclerosis is mostly a microvascular disease, there are striking 
similarities between the two disease processes, leading one researcher to 
describe glomerulosclerosis as, "glomerular atherosclerosis" (Diamond, 1991; 
Moorhead et aI., 1997). It is believed that both processes are initiated by 
endothelial insult (due to mechanical, chemical, bacterial, or viral injury), followed 
by trapping and oxidation of LOL, monocyte recruitment and activation, smooth 
muscle (mesangial) cell proliferation, and fibrous tissue formation (Colwell et aI., 
2001; Lopes-Virella and Virella, 1998; Raptis and Viberti, 2001; Ross, 1999). 
Multiple lines of evidence converge on oxLDL, implicating it as a key pathogenic 
factor in these vascular diseases. First, oxLDL is present in both atherosclerotic 
and glomerulosclerotic lesions, as demonstrated by immunofluorescent staining 
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of human histological sections of samples obtained from both types of lesions 
with monoclonal 'antibodies to oxLDL (Itabe et aI., 1994; Lee and Kim, 1998; 
Magil, 1999). Second, oxLDL appears to have chemotactic properties, 
contributing to the accumulation of monocyte-derived macrophages in both 
atherosclerotic plaques and glomerulosclerotic lesions (Berliner et aI., 1995; 
Berliner et aI., 1990; Kamanna et aI., 1997; Kamanna and Kirschenbaum, 1997; 
Kamanna et ai., 1999; Quinn et at, 1987; Quinn et aI., 1985). Third, oxLDL has 
been demonstrated to induce proliferation of smooth muscle cells in 
atherosclerosis and smooth muscle cell-like mesangial cells in 
glomerulosclerosis, and cause the expansion of the extracellular matrix in both 
types of lesions (Diamond, 1991; Kamanna et aI., 1997; Moorhead et aI., 1997). 
Fourth, oxLDL has been shown to stimulate the transformation of macro phages 
into lipid-laden foam cells, and is considered cytotoxic (Ghosh et aI., 1996; Itabe 
et aI., 1994; Magil, 1999; Salahudeen et aI., 1997; Steinberg, 1993; Steinbrecher 
et aI., 1990). The accumulation of foam cells in lesion sites not only represents a 
hallmark of both atherosclerosis and glomerulosclerosis, but mounting evidence 
pOints to the central importance of these monocyte-derived macrophages in the 
pathogenesis of both lesions (Diamond, 1991; Itabe et aI., 1994; Magil, 1999; 
Mitchinson, 1987; Ross, 1999; Witztum, 1994a) 
LDL-IC and CE Accumulation in Macrophages 
One property of oxLDL, and other modified analogs of LDL, that has received 
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considerable attention from our research group, and several others, is the 
immunogenicity of modified LDL. Even very minor modifications of LDL are 
sufficient to make it antigenic, as reflected by the common presence of oxLDL 
autoantibodies in humans (Lopes-Virella and VireUa, 1996; Steinberg and 
Witztum, 1999; Steinbrecher et al., 1984a; Yla-Herttuala, 1998). Since it is 
reasonable to assume that that these antibodies will bind to their respective 
antigens, provided the antigen is present, an area of growing interest is the 
potential role of oxLDL and oxLDL-containing immune complexes (Ie) in foam 
cell formation, atherogenesis, and glomerulosclerosis (Diamond, 1991; Lopes-
Virella and Virella, 1998; Lopes-Virella et aI., 1999; Magil, 1999). Exploration of 
the role of these Ie in atherosclerosis has led to the observation that oxLDL and 
antibodies reacting with modified lipoprotein particles are present in 
atheros.clerotic plaques, each having been identified and purified from such 
lesions (Palinski and Witztum, 2000; Steinberg et aI., 1989). 
In glomerulosclerosis, antibodies to oxLDL have not yet been separated from 
glomerulosclerotic lesions, and the potential role of oxLDL-IC in diabetic 
glomerulonephritis is unknown. There is, however, evidence suggesting that Ie 
playa role in diabetic nephropathy that comes from the common observation of 
Ie in the glomeruli of patients with diabetic nephropathy, as indicated by 
immunohistochemical staining and the presence of subendothelial high elecron 
density deposits (Ainsworth et aI., 1982; Mazzucco et aI., 2002; Osterby et aI., 
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2002; Severgina et aI., 1994; Yoshikawa et aI., 1990). In streptozotocin-induced 
diabetic rats, the presence of circulating IC was increased and associated with 
IgG deposition in the glomerular mesangium (Abrass, 1984). Additionally, 
diabetic glomerulosclerotic lesions have been reported to be exudative, contain 
foam celis, oxLDL, immunoglobulins, complement, fibrinogen, and albumin· 
(Fioretto and Mauer, 1997, Magil, 1999 #113; Miller and Michael, 1976; Suzuki et 
aI., 2001; Velosa et aI., 1976). 
Focusing on atherosclerosis, a connection between lesion formation and oxLDL-
containing immune complexes has gained substantial recognition during the last 
decade, along with a growing body of evidence suggesting an active participation 
of LDL-IC in this process (Klimov et aI., 1988; Lopes-Virella and Virella, 1994a; 
Lopes-Virella and Virella, 1998; Mironova et aI., 1997; Salonen et aI., 1992; 
Tertov et aI., 1990a; Tertov et aI., 1990b; Yla-Herttuala et ai., 1994). For an 
excellent review of the involvement of LDL-IC and atherosclerosis in diabetes, 
the reader is referred to the 1997 Diabetes Review article by Lopes-Virella et al. 
(Lopes-Virella et aI., 1997b). LDL-IC are believed to be important participants in 
the development of atherosclerosis via several avenues (Figure 5). 
Macrophages ingest LDL-IC more avidly than uncomplexed LDL via the Fey 
receptor I (FcyRI), thus contributing to foam cell formation. The cross-linking of 
Fey receptor by LDL-IC, in-tum, induce the release of pro-inflammatory cytokines 
(Lopes-Virella et aI., 1997a; Virella et at, 1995). 
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Our research group pioneered this area of research, being first to examine the 
effects of presentation of LDL:"containing IC on human monocyte-derived 
macrophages, subsequently engaging in extensive investigations of this 
phenomenon (Gisinger and Lo~es-Virella, 1992; Gisinger et aI., 1991; Griffith et 
aI., 1988; Lopes-Virella et aI., 1997a; Lopes-Virella et aI., 1991; Lopes-Virella et 
aI., 1997b; Lopes-Virella and Virella, 1996; Lopes-Virella and Virella, 1998). 
Research from our group demonstrated that the incubation of monocyte-derived 
macro phages with insoluble LDL-IC prepared with heterologous (rabbit) anti-LDL 
antibodies and human LDL led to massive (approximately 13-fold) intracellular 
accumulation of cholesterol and CE, causing foam cell formation in human 
monocyte-derived macrophages (Lopes-Virella et aI., 1991). This set of 
experiments further indicated that the accumulation of cholesterol and CE 
resulted from a combination of increased uptake and impaired intracellular 
metabolism of the LDL ingested as part of an LDL-containing Ie. The amount of 
LDL in human monocyte-derived macrophages after 5 hours incubation with 
heterologous LDL-IC was 7-fold higher than that observed in control 
macro phages incubated with equal amounts of native LDL. A totally unexpected 
finding was the lack of down regulation of the LDL receptor in macrophages with 
very high levels of intracellular cholesterol (Griffith et aI., 1988), thus allowing 
unregulated uptake of LDL-IC into these lipid-engorged cells via two currently 
recognized receptor-mediated avenues: FcyRI, the primary ingestion pathway, 
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Modified LDL ~ LDL.IC Y J-. Modified lDl Antibodies 
- -....... ~>'l 
Monocyte/Macrophage 
Figure 5. LDL-IC and foam cell formation (adapted from (Shunk, 1993). 
Antibodies are formed against modified LDL (e.g. oxLDL), and complex with their 
antigen, forming LDL-IC. Monocyte/macrophages from the circulation internalize 
the LDL-IC primarily through their FcyRI (Lopes-Virella et aI., 1997a). As a 
consequence, the cells become activated, release cytokines that activate 
endothelial cells, adhere to the endothelium and undergo diapedesis. The CE 
from the lipoprotein core of the LDL component of the LDL-IC is hydrolyzed 
lysosomally and subsequently re-esterified by ACAT. When these lipid-
engorged macrophages contain >50% of their total cholesterol as CE, they are, 
by definition, foam cells. Foam cells, or their immediate precursors, may 
contribute to the progression of the lesion by continuing to secrete various 
cytokines which, for example, promote smooth muscle cell proliferation (Ross, 
1999), cause endothelial cells to express leukocyte adhesion molecules 
(Bevilacqua et aI., 1985; Bevilacqua et aI., 1989; Cavender et aI., 1987), or are 
cytotoxiC (Debets et aI., 1990; Lopes-Virella and Virella, 1998; Nakagawara et 
aI., 1981; Nathan, 1987). Monocyte/macrophages may also produce oxygen 
radicals (Nakagawara et ai., 1981; Nathan, 1987), matrix metalloproteinases 
(Huang et aI., 2000; Musson et aI., 1980), and collagenases (Werb et aI., 1980), 
which could further exacerbate lesion formation by promoting continued 
lipoprotein oxidation, damage to the subendothelial extracellular matrix, and 
damage to other cells in the intima. 
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and, to a much lesser extent, the LDL receptor (Griffith et aI., 1988; Lopes-Virella 
et aI., 1997a). Our research group also showed that the degradation of LDL 
bound to IgG was significantly impaired, barely surpassing the degradation of 
native LDL (1.09-fold higher), and led to a 200-fold increase in intracellular CE 
accumulation (Lopes-Virella et ai., 1991). The characterization of the in vitro 
effects of heterologous LDL-IC was complemented by the demonstration that 
LDL-IC isolated from human sera had similar properties. Klimov et a/. (Klimov et 
al., 1985) demonstrated excessive intracellular cholesterol and CE accumulation 
in mouse peritoneal macrophages exposed to LDL-IC isolated from human 
serum compared to that of macrophages incubated with LDL alone (Klimov et 
aI., 1985). Later, the same investigators reported that LDL-IC isolated from the 
blood of patients with atherosclerosis by immobilized staphylococcal A affinity 
chromatography caused intracellular accumulation of CE in mouse pericardial 
macrophages, and morphological transformation of these cells into foam cells 
(Klimov et aI., 1988). Mironova et al. (Mironova et aI., 1997), working in our 
laboratory, observed significant CE accumulation in human monocyte-derived 
macrophages incubated with human IC isolated from human sera by PEG-
precipitation. 
LDL-IC and Scavenger Receptor ExpreSSion 
As previously mentioned, the experiments with heterologous LDL-IC led us to the 
discovery of a paradoxical upregulation of LDL receptor in macrophages 
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exposed to LDL-IC containing large amounts of intracellular CEo Our studies of 
the binding kinetics of nLDL and macrophages stimulated with LDL-IC showed a 
20-fold increase in LDL binding and that this increase in binding was due to an 
increase in LDL receptor number (Griffith et aI., 1988). This observation was 
confirmed by inhibition of native LDL binding when the receptors were blocked 
using monoclonal antibodies against LDL receptors. Furthermore, up regulation 
of LDL-receptors was an LDL-IC specific phenomenon. When IC were prepared 
with other lipoproteins, including VLDL and HDL, and presented to human 
monocyte-derived macrophages, LDL receptor up regulation was not observed. 
These data are interpreted as suggesting that the increased expression of LDL 
receptors may significantly increase the influx of cholesterol-rich LDL into a cell 
that cannot adequately process accumulated cholesterol and that has lost the 
ability to down regulate LDL receptor expression. 
In a separate series of investigations, Kiener et al. (Kiener et aI., 1995) used a 
similar experimental design to implicated scavenger receptors in a similar 
function. Using phorbol-myristate acetate (PMA) treated THP-1 cells as a 
human monocyte-derived macrophage model, they investigated the effect of 
LDL-IC and acetylated LDL on these cells. After presenting the THP-1 cells with 
LDL-IC, they exposed the cells to acetylated LDL and were able to show an 
increase in intracellular accumulation of acetylated LOL. Following this, they 
discovered that the increase was due to a marked increase in scavenger 
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receptors, and not due to up regulation of LDL receptors. These observations, 
when conjoined--with ours, suggest that LDL-IC transform macrophages into cells 
with exaggerated avidity for LDL, rapidly and actively taking up both native and 
modified forms of this lipoprotein, via LDL receptors and scavenger receptors. 
As a consequence, the cells accumulate cholesterol that they are unable to 
process. In summary, LDL .. IC prepared with human LDL and rabbit anti-LDL 
antibodies appear to be the most efficient mechanism for the transformation of 
human monocyte-derived macrophages into foam cells (Griffith et aI., 1988; 
Lopes-Virella et aI., 1991). These observations needed to be confirmed in 
experiments where homologous LDL-IC made with modified human LDL and 
human anti-LDL antibodies would be incubated with human macrophages. 
LDL-IC and Cytokine Release 
Not only do LDL-IC cause the up regulation of macrophage LDL receptors and 
scavenger receptors, but their ingestion also results in the activation of a variety 
of pro-inflammatory macrophage functions. Researchers in our group have 
observed that LDL-IC are capable of inducing the synthesis and release of 
cytokines (TNF-a and IL-1), and stimulating respiratory burst more efficiently 
than any other Ie (Virella et aI., 1995). 
Cytokine release, which is a common event observed with Ie-activated 
macrophages, is a key step in the inflammation pathway, and has special 
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significance in atherogenesis. For example, in endothelial cells, IL-1 has been 
shown to stimulate the synthesis and surface expression of procoagulant activity 
and platelet activating factor (Bevilacqua et aI., 1984; Breviario et aI., 1988). 
Platelet activating factor can interact with granulocytes and directly or indirectly 
cause increased vascular permeability (Martin et aI., 1988), and induce a positive 
feedback mechanism (Warner et at, 1987) causing even more release of IL-1 
from endothelial cells, and induce expression of platelet-derived growth factor AA 
(PDGF-AA). PDGF-AA can then trigger fibroblast and smooth muscle cell 
proliferation through an autocrine growth-regulating mechanism (Raines et aI., 
1989). In addition to the effects of IL-1, TNF-a is known to induce similar 
responses, such as cell membrane expression of procoagulant activity and 
production of IL-1 by endothelial cells (Hansson et aI., 1989; Nawroth et aI., 
1986). Both TNF-a and IL-1 can increase endothelial expression of VCAMs, 
promoting the adherence of monocytes/macrophages (Beekhuizen and van 
Furth, 1993; Cybulsky and Gimbrone, 1991; Pohlman et aI., 1986). Added to 
this, foam celis, or their macrophage precursors, may contribute to the 
progression of the lesion by secreting various cytokines which act in a variety of 
ways, to include promoting smooth muscle cell proliferation (Ross et aI., 1990), 
causing endothelial cells to express adhesion molecules (Bevilacqua et aI., 1985; 
Bevilacqua et aI., 1989; Cavender et aI., 1987), or be cytotoxic (Debets et aI., 
1990; Lopas-Virella and Virella, 1998; Nakagawara at ai., 1981). 
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In glomerulosclerosis, the accumulation of foam cells is also associated with 
disease- progression (Klahr -et aI., 1988; Magil, 1999; Rovin and Schreiner, 1991). 
Amongst the pathogenetic alterations observed are glomerular remodeling 
caused by the release of growth factors (Lovett et aI., 1983; Nathan, 1987), and 
glomerular functional changes via the elaboration of cytokines (Schreiner and 
Kohan, 1990). Additionally, there is a growing body of evidence implicating 
monocyte chemoattractant protein-1 (MCP-1), a specific chemoattractant for 
monocytes, in recruiting and activating monocytes/macrophages to the 
glomerulus in proliferative glomerular diseases (Banba et aI., 2000; Murphy, 
1994; Oppenheim et at, 1991; Ravin et aI., 1992; Santriano et aI., 1993; 
Yoshimura and Leonard, 1990). 
LDL-IC and Endothelial Cell Damage 
Since endothelial insult is considered to be an initiating factor in atherogenesis 
and glomerulosclerosis, appreciable research emphasis has focused on 
identifying factors that may be involved in it. Though not in the scope of this 
thesis, modified lipoproteins have long been implicated in vascular endothelial 
cell dysfuntion (Kamanna et aI., 1997; Kamanna et aI., 1999; Lopes-Virella and 
Virella, 1996; Ross at aI., 1984). However, in addition to the direct effects of 
modified LDL on the endothelium, it is suspected that the activation of 
macrophages by insoluble LDL-IC may exert an indirect pathogenic effect on 
endothelial cells by generating reactive oxygen species (Virella et aI., 1995) and 
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causing free radical damage, while promoting the oxidation of LDL. Yet another 
indirect pathogenic action of LDL-IC is through the formation of foam cells. 
These lipid-laden monocyte-derived macrophages may add further insult to the 
endothelium through the release of matrix metalloproteinases (Huang et aI., 
2000; Nathan, 1987). Additionally, a significant proportion of the damage 
induced by these cells is widely attributed to the release of superoxide radicals, 
and other reactive oxygen species which can cause increased oxidation of cell 
membrane lipids, among other effects (Baynes, 1991; Berliner et aI., 1995; 
Boyce et aI., 1989; Colwell et aI., 2001; Hunt et aI., 1993; Hunt and Wolff, 1991; 
Virella et aI., 1995; Witztum, 1994a). 
LDL-IC and Fc-y Receptors 
Having shown that LDL-IC can induce foam cell transformation in human 
monocyte-derived macrophages and cause these cells to express 
proinflammatory cytokines, two issues remain unanswered. First, how is it that 
LDL-IC interact with the macrophage; and second, how do these complexes 
become associated with damaged endothelium? 
Regarding the interaction of monocyte-derived macrophages and LDL-IC, there 
is convincing evidence suggesting that LDL-IC is taken up Fc-y receptors (Fc-
yR). The first report of this came from the studies of Gisinger et a/. (Gisinger et 
aI., 1991), where they demonstrated that competing with heat aggregated 
gamma globulin (HAGG) effectively blocked CE accumulation in macro phages 
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incubated with LDL-IC. Blocking with native LDL and- acetylated LDL had 
minimal effect on macrophage CE accumulation, ruling out the significant 
participation of LDL receptors and scavenger receptors, respectively. 
Subsequent studies have identified FcyRI and FerRl1 as primary participants in 
the ingestion of LDL-IC by human monocyte-derived macrophages (Lopes-
Virella et aI., 1997a; Morganelli et ai., 1995). The role of FcyR in the receptor-
mediated uptake of LDL-IC was recently validated, when Shaw et al. reported 
that oxLDL-IC prepared with IgG-Fab fragments, which are not recognized by 
Fey receptors, were not ingested by macro phages (Shaw et aI., 2001). 
Endothelial cells would be an ideal platform for immobilization of circulating LDL-
IC. Unfortunately, endothelial cells do not normally express FcyR, therefore the 
mechanism by which circulating LDL-IC interact with endothelial cells is unknown 
(Ryan, 1986). One possibility that fits well with the "response to injury" 
hypothesis of atherosclerosis and glomerulosclerosis is that infected or damaged 
endothelial cells have been reported to express FcyR (Bengualid et aI., 1990; 
Bruggeman and van Dam-Mieras, 1991; Cines et aI., 1982; Friedman, 1984; 
Hajjar, 1991; MacCormac and Grundy, 1996; Ryan, 1986). Since many of these 
agents have been associated with atherosclerosis, and have been identified in 
atherosclerotic lesions, it is not unreasonable to suggest that their presence 
could up regulate FcyR in these cells, and thus provide an anchor for soluble 
LDL-IC. Alternatively, IgG/lgG-containing IC might bind to cytoskeleton filaments 
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exposed on the surface of damaged endothelial cells (Bevilacqua et aI., 1986). 
Regardless of the mechanism, once immobilized, an environment would be 
created where IgG-containing LDL-IC could interact with, and activate, 
macrophages and exacerbate lesion formation (Huang et aI., 2000; Virella et aI., 
1995). 
Thesis Purpos~ Statement 
T.he main objective of the research reported in this dissertation was the 
verification of the role of human LDL-IC in diabetic nephropathy and foam cell 
formation. This investigation was suggested by three main observations. First, 
people with diabetes are at increased risk for macrovascular disease 
(atherosclerosis), microvascular disease (glomerulosclerosis), and dyslipidemia. 
Interestingly, atherosclerosis and glomerulosclerosis are somewhat analogous 
processes, sharing several pathogenic characteristics, including the presence of 
lipid-engorged monocyte-derived macrophages (foam cells). Second, foam cells 
are highly suspect participants, not innocent bystanders, in both processes. 
Third, macrophages are transformed into foam cells two ways: endocytosis of 
modified LDL (oxLDL, for example); but most efficiently when they ingest LDL-IC. 
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Based on a review of the literature and research regarding these observations, 
three primary goals were established for this dissertation. 
1) Isolate and characterize oxLDL antibodies that are both free in 
circulation (unbound) and associated with LDL, forming soluble 
LDL-IC in serum. 
2) Determine if LDL-IC are associated with diabetic 
nephropathy/glomerulosclerosis. It has already been shown 
that these complexes have macrovascular (atherosclerosis) 
connections; we tested the hypothesis that their presence was 
also linked to microvascular complications (e.g. 
glomerulosclerosis ). 
3) Determine if LDL-IC made from human oxLDL and purified 
human oxLDL antibodies stimulate foam cell formation. This 
goal was essential to validate the results obtained using LDL-IC 
prepared from human LDL and rabbit antibodies to human LDL 




MATERIALS AND METHODS 
Subjects and Samples 
This study used blood samples Gollected from 1 ,068 subjects with type 1 
diabetes enrolled in the Epidemiology of Diabetes Intervention and 
Complications (EDIC) study between May 1997 and May 2000. Blood was 
collected by venipuncture at the EDIC clinics, clotted at room temperature for 1 
hour and centrifuged to separate serum. EDTA (1 mg/mL) was added to the 
serum to prevent LDL oxidation, serum aliquots were immediately stored at -
70oe, and they were shipped monthly to the Medical University of South Carolina 
on dry ice. Informed consent was obtained from all the subjects included in the 
study. The patients were grouped following American Diabetes Association 
criteria (ADA, 2000) based on the average urinary albumin excretion (UAE) 
values measured in two determinations performed in a two year period, one prior 
to the collection of blood samples, and the other after. Patients excreting <30 
mg/24 hr of albumin in the urine were considered normoalbuminuric; those 
excreting 30 to 299 mg/24 hr were classified as microalbuminuric, and those 
excreting ~300 mg/24 hr were considered macroalbuminuric. Thirty-three 
33 
macroalbuminuric subjects and 29 microalbuminuric were selected for isolation 
of circulating Ie based on their matching with 43 patients with normal 
albuminuria for gender, age (within 4 years), and HbA1 c levels (within 1% , 
except in three cases where the HbA1c was greater than 9.5% and the 
differences exceeded 1 %). A subgroup of 47 patients (22 with normal 
albuminuria, 11 with microalbuminuria, and 14 with macroalbuminuria) was 
randomly selected from the larger group of 105 patients for detailed 
characterization of soluble immune complexes. 
Assay of OxLDL Antibodies 
The concentration of antibodies to oxLDL was determined by the competitive 
enzyme immunoassay previously described (Virella et aI., 1993). The assay is 
based on determining the difference in immunoglobulins binding to immobilized 
oxLDL between two aliquots of the same serum, one of which has been 
absorbed with oxLDL [400 ~g/mL phosphate buffered saline, pH 7.4, containing 
1 % (w/v) bovine serum albumin (PBS-BSA)], while the other has been incubated 
with PBS·BSA alone (unabsorbed aliquot). The enzyme-conjugated antibody 
utilized in the assay was a polyvalent anti-lgG antibody that reacts not only with y 
heavy chains, but also with 1( and A light chains, thus measuring antibodies of all 
isotypes. The assays were calibrated with a series of dilutions of a human 
serum calibrator with known concentrations of oxLDL antibodies (Koskinen et aI., 
1998). The antibody concentrations were calculated from the difference in 0.0. 
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(414 nm) between unabsorbed and absorbed aliquots of the tested sera and 
were expressed in ~g/mL. 
Isolation of Circulating OxLDL Antibodies 
OxLDL antibodies were isolated using a previously described affinity 
chromatography 'protocol (Mironova et aL, 1996; Virella et aI., 2000). In brief, 
freshly isolated LDL was dialyzed against a coupling buffer containing 0.1 mol/L 
of NaHC03 and 0.5 mol/L of NaCI (pH 8.3) and incubated overnight on a rocker 
at 4°C with CNBr-activated Sepharose 4B (Pharmacia Biotech) prepared in 
accordance with the manufacturer's instructions. At the end of this incubation, 
free binding sites were blocked with 0.2 mol/L glycine and, after extensive 
washing and degassing, the gel suspension was transferred to a 
chromatography column and washed thoroughly with PBS, pH 7.4. The column 
was then equilibrated with PBS containing 10 J,1mol CuCI2, and the oxidation was 
allowed to proceed for 18 hr at 37°C. The oxidation reaction was stopped by 
washing the column extensively with PBS containing 300 Jlmol of EDTA and 200 
J.lmol of butylated hydroxytoluene (BHT) per liter followed by five washes, 
alternating coupling buffer and 0.5 molll sodium acetate + 0.5 M NaCI, pH 4. 
Finally, the column was equilibrated with 0.01 molll NaHC03 buffer, pH 8.3. 
To isolate anti-oxLDL antibodies from serum samples, 2 ml of serum was 
diluted in 8 mL of 0.01 mol/l NaHC03 buffer, pH 8.3 and allowed to diffuse into 
the column. After loading, the column was incubated overnight at 4°C, and 
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unbound proteins were washed off with the equilibrating buffer. The bound 
antibodies were eluted with 0.1-moI/L NaHC03 (pH 8.3) buffer containing 0.5 
mollL NaCI. The purified antibodies were dialyzed against PBS, pH 7.4, and 
stored at -20°C until analyzed. 
Immunoglobulin Isotypes in Purified OxLDL Antibodies 
The distribution of immunoglobulin isotypes in the fractions eluted from the 
oxLDL column was determined by quantitating IgG, IgM, and IgA by radial 
immunodiffusion (RID) using low level RID kits purchased from The Binding Site 
Limited, San Diego, CA. The distribution of IgG subclasses in the oxLDL 
antibody elution -was also determined by radial immunodiffusion using low level 
RID kits also purchased from The Binding Site. 
Characterization of Soluble Ie Precipitated with PEG 
A modification of the technique described by Chenais et al. (Chenais et aI., 
1977) was used to preCipitate immune complexes from sera. In brief, a 3 mL 
aliquot of serum was gently mixed under constant and gentle stirring with an 
equal volume of a freshly prepared and sterilized 8% polyethylene glycol (PEG) 
solution in borate buffered saline (88S), pH 8.4, that had been added drop by 
drop. The samples, containing a final PEG concentration of 4%, were incubated 
overnight at 4°C and then centrifuged at 3000 rpm for 20 min. The supernatant 
was discarded and the precipitate was washed once with 14 mL of chilled 40/0 
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PEG in BBS, centrifuged again and gently resuspended at 37°C in 3 mL PBS 
containing 0.01 % EDTA, pH 7.4. Most studies were carried out with freshly 
isolated IC. When necessary, aliquots were stored at -20°C until further testing. 
The protein content of PEG precipitates was measured by a modified Lowry 
assay (Griffith et aI., 1988). The cholesterol content of the precipitated Ie was 
determined by gas chromatography after extraction of the PEG precipitates with 
chloroform:methanol (2:1, v/v) (Hara and Radin, 1978). The apolipoprotein B 
content of Ie was determined by quantitative immunoelectrophoresis (Lopes-
Virella et aI., 1982). 
Isolation of IgG from PEG·Precipitated Immune Complexes 
Aliquots of purified IC stored at -20°C were thawed and warmed to 37°C for 20 
minutes and resuspended by gentle vortexing. The resuspended IC samples 
were loaded onto a protein G column (Pharmacia) and the column was washed 
with 0.1 M NaHC03 + 0.5 M NaCI buffer, pH 8.3. This buffer was used because 
its ionic strength is sufficient to elute human oxLDL antibodies from an 
immobilized oxLDL column, (Mironova et aI., 1996; Virella et aI., 2000) and 
therefore, was expected to dissociate any oxLDL-lgG containing IC, allowing the 
elution of oxLDL while retaining IgG due to the high avidity interaction between 
IgG and protein G. After washing, IgG was eluted using 0.1 M Glycine-HCI-
buffer, pH 2.7; and the fractions were immediately neutralized with 1 M Tris-HCI-
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buffer, pH 9.0. Neutralized eluates were then dialyzed against PBS overnight, 
aliquoted, and stored at -20°C until tested. 
IgG Subclass Distribution in OxLDL Antibodies Purified from PEG-
Precipitated Immune Complexes 
IgG fractions isolated from PEG-precipitated immune complexes, prepared as 
previously described, were thawed, diluted to a total volume of 5 mLs with 0.01 
molll NaHC03 buffer, pH 8.3 and allowed to diffuse into the oxlDl column. 
This column was then incubated overnight at 4°C, and unbound proteins were 
washed away with the 0.01 molll NaHC03 (pH 8.3) equilibrating buffer. 
Following this step the bound antibodies were eluted with O.1-moI/L NaHC03 (pH 
8.3) buffer containing 0.5 mol/L NaCI. The purified antibodies were stored at -
20°C until further testing. The distribution of IgG subclasses in the fractions 
eluted from the oxLDL column was determined by quantitating IgG1, IgG2, IgG3, 
and IgG4 by radial immunodiffusion (RID) using low level RID kits purchased 
from The Binding Site Limited, Birmingham, England. Unfortunately, the initial 
step of separating IgG from the immune complexes precluded isolation and 
quantitation of IgM and IgA antibodies specific for oxlDL in circulating soluble 
immune complexes. 
Determination of the Dissociation Constants (Kd) of Purified Antibodies 
An estimate of the avidity of each purified antibody eluate was obtained through 
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the measurement of ~ (a measure that is inversely proportional to avidity) by 
competitive enzyme immunoassay, using a modification of Friguet's method 
(Friguet et aI., 1985), as adapted to the characterization of oxLDL antibodies by 
Mironova et al. (Mironova et aI., 1996). For this purpose, we coated flat-
bottomed Immulon type I plates with 7.5 f..Lg of oxLDLper well. Purified oxLDL 
antibody was used at a final concentration of 100 )lg/mL. A series of antibody 
aliquots was absorbed using concentrations of the apoS component of oxLDL 
ranging from 7.36 x 10-7 to 1.15 x 10-8 mol/L, calculated using an estimated 
molecular weight of 545kD for apoS. 
Absorbed and unabsorbed samples were incubated in oxLDL-coated plates 
overnight at 4°C, and after this step the samples were processed as described 
for the anti-oxLDL antibody assay. The concentrations of antigen along with the 
absorbance values measured in unabsorbed and absorbed samples were used 
to construct a plot of vIa vs. v where v corresponds to bound antibody and vIa to 
bound antibody/free antigen at equilibrium (Friguet et aL, 1985). The slope of 
the plot was used to calculate the Kct for each sample tested. 
LDL Isolation 
Blood was collected in EDTA (1 mg/mL) from normal volunteers after 12 hours of 
fasting, and plasma was collected after centrifugation. The LDL fraction was 
isolated from whole plasma by sequential ultra centrifugation through a KBr 
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discontinuous gradient and collected as the fraction floating at a density of 1.019 
to 1.063 g/mL using a Beckman L5-50, type 50 rotor, washed by ultra 
centrifugation, dialyzed against a 0.15 M NaCI solution containing 1 mM EDT A, 
pH 7.4 and stored under nitrogen in the dark (Lopes-Virella et aI., 1982). LDL 
preparations were then passed through an Acrodisc filter (0.2 Jlm pore size) in 
order to remove aggregates, and a small aliquot taken for determination of 
protein concentration by the method of Lowry (Lowry et at, 1951). 
LDL Oxidation 
LDL was oxidized using the method described by Steinbrecher (Steinbrecher, 
1987). To remove residual KBr and EDT A, the freshly isolated LDL was passed 
through a PD-10 column (Pharmacia Biotech, Uppsala, Sweden). Phosphate-
buffered saline (PBS), pH 7.4, was oxygenated at 2 liters/min for 10 minutes, 
and CuCI2 was added to a final concentration of 10 Jlmol/L for every 300 J.19 of 
LDL. The LDL final concentration was adjusted not to exceed 1.5 mg/mL, and 
the highest concentration of CUCI2 used was 40J..Lmo1/L when the concentration of 
LDL was between 1.2 and 1.5 mg/mL. Oxidation was carried out at 37°C, and to 
continuously monitor the degree of oxidation, a 100 J..Lg aliquot of the CuCI2 
treated LDL was diluted in 2 mL of PBS and continuously monitored at 37° 
spectrophotometrically using a wavelength of 360 nm for excitation and a 
wavelength of 430 nm to measure fluorescence emission (Cominacini et aI., 
1991). Four to six hours after fluorescence reached its peak (approximately 18 
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hours total time) EDTA and butyl-hydroxytoluene (BHT) was added to the 
incubation mixture at final concentrations -of 300 and 200 -,..tmoI/L, respectively to 
stop the oxidation process. Copper and BHT were removed from the oxLDL 
preparations after termination of the oxidation reaction by overnight dialysis 
against 4 liters of a 0.15 mol/L concentration of NaCI containing 300 Ilmoi/L of 
EDTA, pH 8.0. After dialysis, oxLDL was filtered through a sterile 0.22-llm-pore-
size filter to sterilize and remove aggregates and stored at 4°C. The final protein 
concentration in each preparation was determined by a Lowry assay (Lowry et 
aI., 1951). 
Rabbit Immunization and LDL-hyperimmune antibody isolation 
For immunization, a narrow density cut (1.030-1.050 g/mL) of unmodified human 
LDL was isolated. Each New Zealand White rabbit received a series of 3 
immunizations over a six-week period, and were boosted as needed. For the 
primary immunization, 1 mg of unmodified LDL was mixed with Complete 
Freund's Adjuvant (CFA) to a final concentration of 1mg/mL, and the rabbit was 
injected intramuscularly with 0.5 mL LDUCFA at two bilateral sites. Two weeks 
later, 1 mg of LDL was mixed with incomplete Freund's Adjuvant (IFA) toa final 
concentration of 1 mg/mL, and the rabbit was injected intramuscularly with 0.5 mL 
LDL/IFA at two bilateral sites in different quadrants than the primary 
immunization. Two weeks later, 1 mg of LDL was mixed with sterile PBS and the 
rabbit received a series of ten-1 OO).1L intradermal immunizations. Blood was 
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collected, and the hyperimmune serum was separated and frozen 10-14 days 
after the last immunization. Purified IgG. was obtained from human LDL 
hyperimmune rabbit serum using Protein G Sepharose (Pharmacia Biotech) 
following the manufacturer's instructions. 
Preparation of Heterologous Insoluble LDL-Immune Complexes 
Insoluble immune complexes were prepared by incubating unmodified human 
LDL and rabbit anti-LDL antiserum at a 1:8 dilution in sterile PBS overnight, at 
4°C. The concentrations of LDL and anti-LDL antibody used to prepare the 
immune complexes were determined by a precipitin curve, constructed by 
incubating one milliliter of diluted rabbit anti-LDL antiserum with varying amounts 
of LDL (50-500 Ilg) at 4°C overnight. The following day, the protein content of 
the insoluble LDL-IC was determined after washing the precipitate three times 
with sterile PBS by Lowry assay (Lowry et aI., 1951) calibrated with serial 
dilutions of heavily heat-aggregated IgG containing known amounts of IgG. 
Using the results of precipitin curves, the ratio of antigen:antibody giving the 
greatest amount of precipitate was 200 Jl9 LDL and 1 mL of a 1:8 dilution of our 
rabbit anti-LDL antiserum, with the typical yield being 750 J..19 immune complexes 
per mL of diluted rabbit anti-LDL antiserum. Insoluble LDL-IC preparations were 
sterilized by gamma irradiation. 
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Preparation of Human OxLDL-IC [oxLDL-IC(hu)] 
Human oxLDL-IC were prepared using human oxLDL and purified human oxLDL 
antibodies. To establish the optimal concentrations for the formation of oxLDL-
IC(hu), we performed a precipitin curve experiment in which 400 mg of purified 
human oxLDL antibodies was gently mixed with varying amounts of oxLDL (50-
500 J.1g/mL) in a fixed volume (1 mL) and incubated overnight at 4°C. The 
following day human oxLDL ... IC were precipitated using a modification of the 
technique described by Chenais et al. (Chenais et at, 1977). In brief, an equal 
volume of freshly prepared and sterilized 8% polyethylene glycol (PEG) solution 
in borate buffered saline (888), pH 8.4, was added drop by drop under constant 
and gentle stirring. The samples, containing the mixtures of antigen and 
antibody and a final PEG concentration of 4%, were incubated overnight at 4°C 
and then centrifuged at 3000 rpm for 20 min. The supernatant was discarded 
and the precipitate was gently resuspended in sterile 0.5 mL PBS containing 
0.01 % EDTA, pH 7.4. The protein content of these precipitates was determined 
by the method of Lowry (Lowry at aI., 1951). Using the results of precipitin 
curves, the ratio of antigen:antibody giving the greatest yield of precipitate was 
150 Jl9 oxLDL per 1 mL purified oxLDL antibodies (400 Jlg/mL), with the typical 
yield being 250 Jl9 oxLDL-IC. All studies were carried out with freshly isolated 




The human monocytic cell line THP-1 was obtained from the American Type 
Culture Collection (ATCC, Rockville, MD). THP-1 celis are well recognized for 
their ability to be transformed into macrophage-like cells (Auwerx, 1991). 
Compared to other human myeloid cell-lines, such as HL-60, U937, KG-1, or 
HEL (Figure 6) cell lines, THP-1 cells are more closely related to monocytes. 
Additionally, differentiated THP-1 cells have been shov~'n to mimic monocyte-
derived macrophages morphologically and physiologjca;~y, rnaking them a model 
of choice for studies of monocyte-derived macrophagas (Auwerx, 1991). The 
cells were cultured at 37° C in a 50/0 C02 atmosphere in iscove's modified 
Dulbecco's medium (IMDM) supplemented with 10% fetal calf serum (FCS) 
(Sigma) and antibiotics (penicillin @ 100 U/mL, streptomycin @ 100 )lg/mL, 
amphotericin B @ 0.25 )lg/mL). Transformation of the THP-1 cells into 
macrophages was performed in the medium described above with the addition of 
160 nmol/L phorbol 12-myristate 13-acetate (PMA) for 3 days. After PMA 
treatment the medium was aspirated, the adherent celis were washed 3 times 
with sterile PBS, and the medium was replaced with a specially formulated 
serum free medium (SFM) (Stevenson et aI., 1984) -{or sthi1ulation with varying 
concentrations of oxLDL and oxLDL-IC. The SF[vJ Vias G0mposed of IMDM with 
the addition of bovine serum albumin (fatty acid free, O.4~iQ)~ human transferrin 
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Figure 6. Hematopoietic cell differentiation: outline of the differentiation of 
hematopoietic stem cells. Some of the more frequently used myeloid leukemia 
cell lines are boxed. CFU=colony forming unit; E=erythrocyte; 
GM=granulocyte/monocyte; EO=eosinophil; and mega=megakaryocyte (Auwerx, 
1991 ). 
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(1 J.lg/mL), and L-phosphatidyl choline (1 Jlg/mL) all from Sigma Chemical 
Company (St. Louis, MO): human insulin (0.128 U/mL, Eli Lilly Co., Indianapolis, 
IN); and ferrous chloride (0.07 nM, Fisher Scientific, Fairlawn, NJ). 
Measurement of Free and Esterified Cholesterol Content 
PMA-activated THP-1 cells (1 X 1 06cells) were incubated for 48 hr with human 
oxLDL-IC while oxidized low-density lipoprotein (oxLDL), insoluble oxLDL-IC, and 
SFM were used as controls. After incubation, the medium was removed, the 
cells were extensively washed with PBS, and the cell monolayer was extracted 
with hexane/isopropanol (3:2) (v/v) as previously described (Hara and Radin, 
1978). Free and total cholesterol were assayed on a gas chromatograph 
equipped with a hydrogen flame ionization detector. A fused silica capillary 
column packed with DB 17 was used for chromatographic separation and its 
temperature was maintained at 250°C during the separation. Nitrogen was used 
as the gas carrier. 
To assay total cholesterol, the cellular extracts were evaporated to dryness and 
the residue was hydrolyzed by Ishikawa's method (Ishikawa et aI., 1974) as 
previously described (Lopes-Virella et aI., 1982). Cholesteryl ester levels were 
calculated by subtracting free cholesterol from total cholesterol levels. ~­
stigmasterol was used as an internal standard. After the lipid extraction, the cell 
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pellet was solubilized with 1 M NaOH, and the protein content determined (Lowry 
et aI., 1951). 
Statistical Analysis 
Results are expressed as mean + standard error, unless stated differently. All 
data were analyzed using InStat (GraphPad, San Diego, California) and SAS 
(SAS Institute, Inc., version 8, Cary, N.C.) software. ANOVA, with Bonferroni 
correctio,n, was used to compare the results of different tests in the three UAE 
groups, using the data from patients with normal albuminuria as control. A 
paired t-test between two measurements of oxLDL antibody concentrations in 
serum against concentrations of the same antibodies isolated from LDL-IC was 
conducted. Analysis of covariance (ANOCOVA, Dunnetl-Hsu correction) with 
normal albuminuria as control while adjusting for gender, age, HbA 1 c among 
three UAE groups was performed as indicated. Additional details about 
statistical analysis can be found in the footnotes for table 4 and on the legends 
for figures 10-13. 
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Chapter 3 
Results and Discussion 
Part 1: Characterization of Oxidized LDL Antibodies 
Part 1: Introduction 
In recent years, the role of atherogenic lipoproteins in human disease has been 
the object of intense research. This research has led to increased attention 
focusing on the free radical-mediated oxidative modification of lipoproteins and 
their participation in the development of macrovascular disease (atherosclerosis) 
and microvascular disease (glomerulosclerosis), two diseases found commonly 
in diabetic individuals (Cooper et aI., 1997; Nathan, 1993). In vitro studies have 
revealed the apparent susceptibility of LDL to oxidation by endothelial cells, 
smooth muscle cells, macrophages, and renal.mesangial cells (Cathcart et aI., 
1985; Morel et aI., 1984; Parthasarathy et aI., 1986; Steinbrecher et aI., 1984b; 
Wheeler et aI., 1994); and that oxidized LDL is present in atheromatous and 
glomerulosclerotic lesions (Itabe et aI., 1994; Lee and Kim, 1998; Magil, 1999; 
Schlondorff, 1993; Yla-Herttuala et aI., 1994). These observations have led to 
the belief that oxLDL is somehow involved in both processes. 
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Although atherosclerosis is generally recognized as a macrovascular disease 
and nephropathy is primarily a microvascular disease, they share several 
pathogenic similarities supported by a growing body of evidence suggesting that 
atherosclerosis and glomerulosclerosis are indeed analogous pathological 
processes (Diamond, 1991; Moorhead et aI., 1997). OxLDL is a suspected 
active participant in both processes, and several theories have been proposed to 
explain how it appears to contribute to both processes. OxLDL is atherogenic 
(Steinberg and Witztum, 1999). It is known to induce chemotaxis and the 
recruitment of monocytes into the vascular intima, where monocyte-derived 
macrophages avidly ingest it via several types of scavenger receptors, greatly 
enhancing intracellular cholesterol accumulation and foam cell formation 
(Steinberg, 1993; Yla-Herttuala, 1998), with foam cells being well recognized 
hallmarks of both lesions (Guijarro and Keane, 1994; Kamanna et aI., 1997; 
Lopes-Virella and Virella, 1998; Magil, 1999; Schwartz et aI., 1991). Additionally, 
oxLDL causes endothelial cell dysfunction by upregulating expression of cell 
adhesion molecules, effectively enhancing the adhesion/interaction of 
monocytes and endothelial cells; and is known to be cytotoxic to cultures of 
vascular endothelial cells, glomerular endothelial cells, mesangial cells, and 
smooth muscle cells (Berliner et at, 1990; Jeng at aI., 1993; Kamanna et aI., 
1999; Morel et aI., 1983; Shiozawa, 2000; Steinberg and Witztum, 1990). 
It is common knowledge that post-translational modification of LDL renders the 
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lipoprotein immunogenic, enabling it to interact with the immune system and 
generate the formation of antibodies (Steinbrecher et aI., 1984a). In fact, 
autoantibodies binding to various epitopes of oxLDL have been described in 
humans, rabbits, and mice (Lopes-Virella et aI., 1999; Orchard et aI., 1999; 
Orekhov et aI., 1991 b; Palinski et aI., 1994; Palinski et aI., 1989; Parums et aI., 
1990). Interestingly, anti-oxLDL antibodies and LDL-IC have been detected in 
human sera with relatively high frequency, and the atherogenic potential of LDL-
IC is attested to by a large body of experimental data suggesting that incubation 
of LDL-IC and human monocyte-derived macrophages severely disrupts the 
cell's cholesterol metabolism, leading to massive lipid accumulation in these 
macrophages (Gisinger and Lopes-Virella, 1992; Gisinger et aI., 1991; Griffith et 
aI., 1988; Klimov et al., 1985; Klimov et aI., 1988; Lopes-Virella et aI., 1991; 
Orekhov et aI., 1991 a; Orekhov et aI., 1991 b; Palinski et aI., 1989; Salonen et 
aI., 1992; Tertov et aI., 1990a; Virella et aI., 1993). In our laboratory, we have 
conclusively shown that co-incubation of LDL-IC and monocyte-derived 
macrophages induce foam cell formation more efficiently than any other known 
stimulus. Additionally, work from our research group has demonstrated the 
ability of LDL-IC to activate macrophages and to cause cytokine release (activate 
macrophages), while simultaneously promoting foam cell·formation through a 
paradoxical increase in LDL receptors and scavenger receptors (Ghosh et aI., 
1996; Gisinger and Lopes-VireJla, 1992; Lopes-Virella et aI., 1991; Virella et aI., 
1995). 
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In light of these observations, it seems logical that there would be keen interest 
in determining if oxLDL antibody titers are clinically useful in either reflecting or 
predicting the severity index of atherosclerosis and/or glomerulosclerosis. 
Surprisingly, studies examining an association of oxLDl antibody titers and 
nephropathy are sparse and the results conflicting. While some groups have 
reported a positive correlation between oxLDl antibody titers and nephropathy, 
others have reported no significant differences in oxLDL antibody levels between 
groups with and without nephropathy (Bellazzi et at, 1993; Korpinen et aI., 1997; 
Leinonen et aI., 1998). Similar studies in atherosclerosis are not only more 
numerous, but have fueled spirited discussions. Many of these studies have 
reported elevated autoantibody titers in subjects with increased cardiovascular 
risk factors or clinically manifest atherosclerosis, including coronary artery 
disease, myocardial infarction, peripheral vascular disease, and hypertension 
(Bergmark et aI., 1995; Branch et aI., 1994; Heitzer et aI., 1996; Halvoet et aI., 
1999; Maggi, 1994; Puurunen et aI., 1994). In contrast, an equally impressive 
number of studies, including observations from our laboratory, have found no 
correlation between the titers of circulating oxLDL antibodies and clinical 
indicators of atherosclerosis; and, interestingly, one group even reported a 
negative correlation (Festa et aI., 1998; Lopes-Virella et aI., 1999; Maggi, 1994; 
Mironova et al., 1997; Orchard et al., 1999; Virella et aI., 1993). 
These conflicting data may be due, at least in part, to small sample size, 
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sampling demographics, or to differences in screening methodologies. It is 
hoped that large-scale clinical studies currently underway and standardization of 
oxLDL antibody testing protocols may help resolve these issues. However, the 
relationship between oxLDL antibody titers and the severity of atherosclerosis, or 
glomerulosclerosis, is undoubtedly complex and may involve the interaction of 
one or more of the following scenarios: 1) Accurate determination of the overall 
burden of atherosclerosis/glomerulosclerosis is problematic, leaving the real 
possibility that non-invasive measurements do not accurately reflect the extent of 
disease; 2) Measuring free oxLDL antibody titers may be inaccurate because an 
unknown quantity of oxLDL antibodies may be bound to circulating antigens, 
forming LDL-IC, as has been reported by our research group in subjects with 
diabetes (Lopes-Virella et aI., 1999; Mironova et aI., 2000; Mironova et aI., 1997); 
3) OxLDL antibodies may combine with oxLDL in circulation or in tissues other 
than arteries and the kidneys, allowing the arteries and kidneys to remain 
relatively free of pathological changes in spite of high levels of oxLDL antibody. 
In light of these potential pitfalls, and the fact that more than one of the above 
processes may be involved, it is surprising that an appreciable number of studies 
found a correlation between atherosclerosis, or glomerulosclerosis, and oxLDL 
antibody titers at all. 
Therefore, we decided to isolate and characterize free and Ie-bound oxLDL 
antibodies from human sera to confirm their presence and to attempt to find 
52 
answers to these conflicting reports. This stimulus has led to considerable effort 
from our research group directed toward isolating and characterizing human 
oxLDL antibodies from serum and oxLDL-IC. The task at hand is ongoing, and 
began with the isolation and characterization of oxLDL antibodies from the serum 
of eight subjects (Mironova et aI., 1995), and subsequently was expanded to 
include the characterization of oxLDL antibodies isolated from serum and Ie 
from 46 subjects. The following results report the fiJldings of this portion of our 
study. 
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Part 1: Results 
Characterization of free serum oxLDL antibodies: oxLDL antibodies were 
isolated from the serum of 46 subjects with type 1 diabetes, using a column 
containing oxLDL cross-linked to Sepharose, as described in Materials and 
Methods. Serum concentrations of oxLDL immunoglobulin isotypes (Figure 7) 
and IgG subclasses (Figure 8) were determined by radial immunodiffusion (RID). 
The predominant immunoglobulin isotype was IgG (83%), exceeding IgM (140/0) 
by a factor of 6. The amount of IgA (30/0) oxlDl antibodies isolated from serum 
was minimal. Quantification of IgG subclasses demonstrated a predominance of 
IgG1 and IgG3, with IgG1 accounting for 72% of the totallgG levels and IgG3 
making up 21 0/0. The average affinity of free oxlDl antibodies was determined 
via the dissociation constant (Kd) and found to be 1.13 + 0.13 x 10-8 molll. 
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Figure 7. Immunoglobulin isotypes of oxLDL antibodies isolated from 
serum of human type 1 diabetic subjects (N=46). Antibodies were 
isolated using an oxLDL cross-linked to Sepharose column. 
Immunoglobulin isotypes were determined by radial immunodiffusion. 
























Figure 8. IgG subclass distribution of oxLDL antibodies isolated from serum of 
human type 1 diabetic subjects (N=46). Antibodies were isolated using an 
oxLDL cross-linked to Sepharose column. IgG subclasses were determined by 
radial immunodiffusion. The data in the graph is expressed as mean (mg/L) ± 
SEM. 
56 
Characterization of oxLDLantibodies isolated from immune complexes: 
The isolation of oxLDL antibodies from immune complexes was a complex 
multiple-step process that began with the precipitation of soluble immune 
complexes present in serum, using a final concentration of 4% PEG. After 
precipitating this heterogeneous mixture of immune complexes, we purified 
polyclonal IgG from the immune complexes, and then measured anti-oxLDL 
activity in the purified IgG. This was not an easy task, and involved a 
modification of a technique developed previously in our laboratory (Mironova et 
aI., 1997). This technique utilized a protein G column (Pharmacia) to separate 
IgG from immune complexes. However, the apparent affinities of oxLDL 
antibodies purified in this manner were lower than the affinities of serum (free) 
antibodies [unpublished data], and the purified IgG fraction was found to 
contained LDl. To overcome this limitation, we capitalized on the observation 
that a high salt buffer could disrupt the antigen:antibody interaction of oxLDL-IC, 
while having a relatively minimal effect on the binding of IgG to protein G. This 
process allowed us to capture immune complex-associated IgG on a protein G 
column, dissociate oxlDl, and recover oxLDl-free IgG antibodies for further 
testing. Using this protocol, we purified IgG oxLDl antibodies from IC, and 
determined their Kd. We found that the avidities of oxLDl IgG antibodies 
isolated from immune complexes appeared to be higher than the affinities of free 
oxLDL antibodies isolated from serum (0.86 ±O.1 x 10-8 vs. 1.13 ±O.1 x 10-8 
molll; p< 0.05). Additionally, we were able to determine the IgG subclass 
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distribution of oxLDL antibodies (Figure 9) from the Ie-derived IgG isolates of 9 
subject's sera by purifying the oxLDL antibody fraction of IgG, using oxLDL 
cross-linked to Sepharose ,column, and found it not significantly different than 
that of free oxLDL antibodies isolated from serum. 
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Figure 9. Immunoglobulin IgG subclasses oxLDL antibodies isolated from PEG-
precipitated immune complexes of human type 1 diabetic subjects (N=9). IgG 
subclasses were determined by radial immunodiffusion, using IgG antibodies 
purified from PEG-precipitated immune complexes by a combination of protein G 
affinity chromatography in oxLDL-specific antibodies using an oxLDL cross-
linked to Sepharose. The data in the graph is expressed as mean (mg/L) ± 
SEM. 
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Part 1: Summary 
Isotypic characterization of free oxLDL antibodies isolated from serum 
demonstrated that IgG was the primary isotype, accounting for more than 800/0 of 
the isolated oxLDL antibodies, followed by small amounts of IgM and minute 
amounts of IgA. The IgG subclass distribution observed in the purified oxLDL 
antibodies showed predominance of IgG1 and IgG3, with similar profiles being 
observed in oxLDL antibodies isolated from IC. We view this finding as 
significant because these IgG subclasses are efficient activators of complement, 
and interact with the three types of FcyR; therefore, appear capable of forming 
immune complexes with proinflammatory properties (Virella, 2001), and warrant 
further investigation. An EIA-based determination of oxLDL avidities showed 
that oxLDL antibodies isolated from serum had higher dissociation constants 
(Kd) than those observed in oxLDL antibodies isolated from immune complexes 
(Kd = 1.13 + 0.13 x 10-8 molll vs. 0.86 + 0.06 x 10-8 mol/L; p<O.05), indicating 
that immune complexes are formed with oxLDL antibodies of higher avidity than 
that of antibodies that remain in circulation. 
Collectively, these findings indicate a possible pathogenic role for oxLDL 
antibodies and the oxLDL-IC they help form. Our data strongly suggest that 
oxLDL antibodies are predominantly of isotypes and subclasses able to interact 
with Fc receptors on phagocytic cells and to activate complement, therefore, are 
considered proinflammatory. The observation that the avidity of antibodies 
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isolated from soluble Ie exceeds the avidity of free antibodies isolated from 
serum suggests that antibodies of oxLDL are of sufficiently high avidity to form 
stable IC. These observations, furthermore, indicate that LDL-IC formation may 
help explain the discrepant association of oxLDL antibody levels and 
atherosclerosis/glomerulosclerosis. It seems reasonable that these Ie 
concentrations may have a stronger'correlation with vascular disease than that 
of oxLDL antibody levels alone. Considering the potentially proinflammatory 
nature of the antibodies involved in oxLDL-IC formation, further studies 
examining the association of oxLDL-IC and vascular disease are needed, as well . 
as in vitro investigations examining the potential role of Ie in atherosclerotic and 
glomerulosclerotic disease models. 
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Part 2: Antioxidized LDL-Containing Immune Complexes in Diabetic 
Nephropathy 
Part 2: Introduction 
It is well known that people with type 1 diabetes are at increased risk of 
developing microvascular and macrovascular diseases (Lloyd et aI., 1996; Maser 
et aI., 1991; Orchard et aI., 1990; Raskin, 1994), with macrovascular disease 
being the leading cause of morbidity and mortality in this group. In toto, these 
complications translate into an increased likelihood of ischemic heart disease, 
stroke, amputation, kidney failure, and blindness. Interestingly, nephropathy, a 
microvascular complication of diabetes, has been shown to accelerate 
atherosclerosis in patients with diabetes, and has been identified as a significant 
independent riskfactor for macrovascular disease (De Cosmo et aI., 1997; 
Ishimura et aI., 2001; Jensen et aI., 1987), suggesting that the two processes are 
interrelated. Several hypotheses have been put forward to explain how 
nephropathy accelerates the development of macrovascular disease. The most 
commonly accepted hypothesis postulates that abnormalities in lipoprotein 
metabolism secondary to nephropathy lead to the formation of atherogenic 
lipoproteins and, as a consequence, to the accelerated development of 
atherosclerosis (Groop et aI., 1996; Hirano, 1999). Some of the better 
characterized lipoprotein changes in nephropathy include LDL glycation and 
oxidation - the former enhancing the formation of oxidized LDL (oxLDL) as well 
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as of advanced glycated end-products (AGE)-LDL (Salahudeen et aI., 1997). 
OxLDL and AGE-LDL playa role not only tn the development of atherosclerosis 
but also in the development of nephropathy (Diamond, 1991; Raptis and Viberti, 
2001; Witztum, 1994a). Our present study is mainly focused on the role of 
oxidized LDL, independently, and as a component of oxLDL-containing immune 
complexes (oxLDL-IC), i,n the pathogenesis of diabetic nephropathy. 
OxLDL has been del110nstrated in both atherosclerotic plaques and in 
glomerulosclerotic lesions, where it appears to be actively involved in lesion 
formation. It stimulates monocyte endothelial cell interactions (Berliner et aI., 
1990; Shi et ai., 2000), and acts as a chemoattractant, recruiting macrophages 
into atheromatous as well as into glomerulosclerotic lesions (Diamond, 1991; 
Kamanna et aI., 1999; Kamanna et aI., 1996; Kaplan and Aviram, 1999; Takaku 
et aI., 1999; Witztum, 1994b). After recruitment of macrophages into the lesions, 
these cells take up oxLDL and are transformed into foam cells, hallmarks of both 
lesions (Itabe et at., 1994; Kamanna et aI., 1997; Lopes-Virella and Virella, 1998; 
Magil, 1999). Besides inducing accumulation of foam cells in both 
atherosclerotic and glomerulosclerotic lesions, oxLDL induces cell proliferation 
(smooth muscle cells in atherosclerotic lesions and mesangial cells in 
glomerulosclerosis) and causes expansion of extracellular matrix in both 
processes via mechanisms that are both complex and poorly defined (Diamond, 
1991; Han and Pak, 1999). Although the exact mechanisms are not known, 
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macrophages undoubtedly occupy a pivotal role in these processes based on the 
observation that they' secrete a variety ofcytokines, including transforming 
growth factor-J3 which contributes to the expansion of the extracellular matrix via 
fibronectin, collagen, and proteoglycan synthesis; and IL-1 ~ which is known to 
induce proliferation of vascular smooth muscle cells and mesangial cells (Ku et 
aI., 1992; Nathan, 1987; Tesch et aL, 1997). 
One property of oxLDL that has attracted considerable attention is its 
immunogenicity, as reflected by the formation of oxLDL autoantibodies (Lopes-
Virella and Virella, 1998; Lopes-Virella et aI., 1999; Steinbrecher et aI., 1984a). 
Evidence for the involvement of humoral immune factors including 
autoantibodies against modified forms of LDL in atherogenesis has been 
supported by data from experimental models and clinical studies (Bergmark et 
aI., 1995; Griffith et aI., 1988; Kiener et aI., 1995; Klirnovet aI., 1988; Lopes-
Virella et aI., 1991; Lopes-Virella and Virella, 1994a; Mironova et aI., 1997; 
Orchard et aI., 1999). In humans, LDL-containing immune complexes (LDL-IC) 
are present in the blood of subjects with and without demonstrable vascular 
disease (Klimov et aI., 1988; Mironova et aI., 1997; Tertov et aI., 1990a; Tertov et 
aI., 1990b), and appear to contribute to atherosclerosis via enhanced intracellular 
cholesterol and cholesteryl ester accumulation in macrophages, as well as their 
ability to activate macrophages (Klimov et aI., 1988; Lopes-Virella and Virella, 
1996; Tertov et aI., 1990a; Tertov et aI., 1990b; Virella et aI., 1995). Studies 
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performed in our laboratory (Griffith et aI., 1988; Lopes-Virella et aI., 1991) have 
shown that co-incubation of human monocyte-derived macrophages with 
heterologous LDL-IC prepared with human LDL and rabbit anti-LDL antibodies is 
the most efficient mechanism for inducing foam cell formation. Similar 
observations have also been reported using immune complexes isolated from 
human serum (Mironova et aI., 2000; Mironova et aI., 1997). -In contrast, studies 
examining the possible correlation between the levels of Circulating oxLDL 
antibodies and clinical evidence of atherosclerosis have yielded contradictory 
and inconclusive results (Bergmark et aI., 1995; Festa et aI., 1998; Klimovet al., 
1988; Lopes-Virella et aI., 1999; Maggi, 1994; Orchard et aI., 1999). 
Furthermore, the pathogenic role of oxLDL antibodies has recently been 
questioned in two animal studies, wherein the immunization of LDL-receptor 
deficient rabbits (Palinski et aI., 1995) and apo-E deficient mice (George et aI., 
1998) with MDA-LDL appeared to have a protective atherogenic effect. The 
interpretation of these results to suggest an atherogenic protective role for 
humoral immunity to oxLDL in humans (Wick and Xu, 1999) is problematic 
because the studies were performed using genetically altered animals, the titers 
of antibodies in immunized animals were higher than those measured in 
nonimmunized animals, the isotype and avidity of elicited antibodies was not 
characterized, and a later study demonstrated that the protective effect of 
immunization was not due to oxLDL antibody production (Freigang et aI., 1998). 
The lack of correlation between concentrations of circulating antibodies and 
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parameters indicative of atherosclerosis. in humans may be explained, at least in 
part, by the interference of circulating immune complexes in oxLDL antibody 
assays. We have previously reported an inverse correlation between the serum 
concentrations of oxLDL antibodies and of LDL-containing immune complexes 
(Lopes-Virella et aI., 1999; Mironova et aI., 1997). Thus, the paradoxical inverse 
correlation between circulating oxLDL antibodies and vascular disease may 
result from the u,nderestimation of oxLDL antibody levels due to the presence of 
large concentrations of circulating oxLDL-IC (Lopes-Virella et aI., 1999; Mironova 
et aI., 1997). Also, the antibodies responsible for IC formation could be of higher 
avidity than those that remain free in serum. As a consequence, the resulting 
immune complexes would be relatively stable and more able to cause 
inflammatory reactions in sites of formation or deposition. In contrast, the free 
circulating antibodies, of lower avidity, may not even playa pathogenic role. The 
direct correlation observed between LDL-IC levels and the development of 
coronary heart disease reported by us in a previous study certainly supports this 
interpretation of the experimental facts (Lopes-Virella et at., 1999). 
An attractive hypothesis to explain the better correlation between LDL-IC and 
atherosclerosis is that the oxLDL antibodies responsible for Ie formation are of 
higher avidity than those that remain free in serum. As a consequence, the 
resulting immune complexes would be relatively stable and more able to cause 
inflammatory reactions in sites of formation or deposition. In contrast, the free 
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circulating antibodies, of lower avidity, may not even playa pathogenic role. 
In light of the hypothesis that atherosclerosis and glomerulosclerosis share 
pathogenic factors (Diamond, 1991; Kamanna et aI., 1997), and of our previous 
observation of a positive correlation between atherosclerosis and LDL-IC, along 
with a negative correlation with free oxLDL antibodies, we decided to investigate 
if the levels and characteristics of LDL-IC correlated with diabetic nephropathy. 
In the current study, we have tested the hypothesis that nephropathy is 
associated with the concentration of circulating immune complexes containing 
oxLDL, not with free antibody against oxLDL, that the avidity of antibodies 
leading to immune complex formation is higher than the avidity of those 
antibodies remaining free in circulation, and that diabetic subjects with increased 
albuminuria have oxLDL antibodies in their LDL-IC of higher avidity than patients 
without albuminuria. To answer these objectives, we have determined in 105 
subjects with type I diabetes, subdivided into 3 groups according to their degree 
of albuminuria (an index of nephropathy), the concentration and avidity of free 
circulating oxLDL antibodies, as well as the concentration and avidity of these 
antibodies in circulating immune complexes. . 
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Part 2: Results 
The clinical and laboratorial characteristics of the 3 subgroups of subjects 
studied are summarized in table 4. The three subgroups were closely matched, 
by design, for gender, age, and degree of glycemic control at the beginning of 
the study. Significant differences in their lipid profile were observed, as 
expected. As shown in table 4, when compared to the subjects with 
normoalbuminuria, the subjects with macroalbuminuria had increased levels of 
total cholesterol and triglycerides that reached statistical significance, while the 
patients with microalbuminuria has significant lower levels of HDL-cholesterol 
than those with macroalbuminuria or normoalbuminuria. The levels of circulating 
oxLDL antibodies in the 3 subgroups studied were increased in the groups with 
microalbuminuria and macroalbuminuria relative to the normoalbuminuric group. 
However, the increase did not reach statistical significance (p=O.0885). A trend 
analysis comparing UAE with concentrations of circulating oxLDL antibodies also 
failed to achieve statistical significance (p=O.0520). 
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TABLE 4 - Characteristics of selected study subjects from DCCT/EDIC 
cohort 
Narmaalbuminuric Micraalbuminuric Macroalbuminuric 
N 43 29 33 
Sex (male/female) 33/10 23/6 25/8 
Age (years) 40±8 40±8 40±8 
HbA1c(%) 8.7±1.1 9.2±1.3 9.0 ±1.3 
Chal (mg/dL) 189±33 188±33 215±40 
HDL (mg/dL) 56±12 49±10 57±15 
LDL (mg/dL) 117±30 117±25 130±26 
TGL (mg/dL) 81±53 114±69 139±85 










Data are means ± SD. Statistical significance was determined by an ANOVA 
among three matched groups with contrast to normal albuminuria as a control 
group, testing within-group differences.' 
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Measurement of oxLDL antibodies, cholesterol and apolipoprotein B was 
performed in immune complexes isolated by precipitation with 3.5% of PEG. 
There was no significant difference in the concentrations of oxLDL antibodies in 
the PEG precipitates (data not shown). However, as shown in figure 10A, the 
mean total cholesterol concentration in PEG precipitates was higher in the 
macroalbuminuric (272±20 mg/L) and microalbuminuric (244±20mg/L) groups, 
compared to the normoalbuminuric group (204+18 mg/L). The difference 
between the cholesterol content of IC in normoalbuminuric and 
macroalbuminuric groups reached statistical significance (p<O.03). Additionally, 
levels of apolipoprotein B in PEG precipitates showed similar increases in the 
macroalbuminuric (134+10 mg/L) and microalbuminuric (110+11 mg/L) groups 
compared to the normoalbuminuric group (99+9 mg/L), with the difference 
reaching statistical significance when the macroalbuminuric and 
normoalbuminuric groups were compared (p<0.03, figure 108). These data 
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Figure 10: Total cholesterol (A) and Apolipoprotein 8 (8) levels in 
polyethylene glycol-precipitated immune complexes of 105 type l ' diabetic 
subjects with varying degrees of nephropathy: 43 subjects had 
normoalbuminuria, 29 had microalbuminuria, and 33 subjects had 
macroalbuminuria. 0.5 mL serum was precipitated with polyethylene glycol 
and cholesterol was extracted using a chloroform:methanol mixture (2:1, v/v). 
Cholesterol levels were determined using gas chromatography. 
Apolipoprotein B levels were determined using quantitative 
immunoelectrophoresis. Results are given in mg/L and data is expressed as 
mean ± SEM. Statistical significance was determined by an analysis of 
covariance (ANOCOVA) with normal albuminuria as control group when 
adjusted for gender, and age, and HbA 1 c. A Significant difference was 
observed between the contents of cholesterol and apolipoprotein B in PEG-
precipitated Ie between the group of patients with macroalbuminuria and the 
group of patients with normal levels of urinary albumin. 
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The presence of cholesterol and apolipoprotein B in PEG precipi,tates does not 
prove that the . precipitated LDL is oxLDL. 'However, we have obtained strong 
indirect evidence for the presence of oxLDL in PEG precipitates by isolating IgG 
antibodies specific for oxLDL from PEG precipitates. We started by fractionating 
PEG precipitates by affinity chromatography using immobilized streptococcal 
protein G. Using conventional chromatography conditions that involved washing 
unbound proteins from the protein G column with 20 mM sodium phosphate 
buffer, pH 7.0, small concentrations of cholesterol are uniformly present in the 
IgG fraction eluted with O.2M glycine-HCI buffer, presumably indicating the 
retention of Iipoprotein-lgG complexes in the column. The presence of LDL-IC in 
the IgG eluates is undesirable because it potentially interferes with the assay of 
oxLDL antibody avidity. To avoid this problem, we modified the elution protocol 
so that we could dissociate LDL-IC while retaining the absorbed IgG, wash out 
the dissociated LDL, and elute antigen-free IgG {table 5}. To this end, we 
washed the protein G column with 0.1 M NaHC03 pH 8.3 buffer containing O.5M 
NaCI. Under these conditions, the IgG eluted with O.2M glycine-Hel, pH 2.7 was 
virtually devoid of cholesterol {cholesterol was undetectable in three out of four 
eluates}. The IgG fractions obtained with both protocols contained oxLDL 
antibodies, measured by our competitive immunoassay. The recoveries of IgG 
and of oxLDL antibody did not differ Significantly with the two different elution 
protocols. It must be noted that the recovery of oxLDL antibody was in apparent 
excess of the amount loaded in the column, this being at least in part, a 
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consequence of the interference of Ie in the assay of oxLDL antibody. Also, 
when the concentrations of oxLDL antibodies in serum and PEG precipitated 
immune complexes were compared, the levels measured in the IgG fraction 
isolated from the PEG precipitates were significantly higher than the levels 
measured in serum (Figure 11). The presence of significant amount of oxLDL 
antibodies in the purified IgG fraction confirmed our assumption that PEG-
precipitated circ~lating immune complexes contain oxLDL complexed with its 
corresponding antibody in subjects with type 1 diabetes. Interestingly, we 
detected small amounts of oxLDL antibodies in protein G washout fractions, 
most probably corresponding to immune complexes containing immunoglobulin 
isotypes not bound by protein G (primarily IgA and IgM). 
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Table 5. Comparison of elution protocols for isolation of IgG from PEG 
precipitates of four different individuals. A PEG precipitate was fractionated in a 
protein G column in triplicate under two sets of elution conditions. 
Original elution protocola Modified elution protocolD 
Initial load Cholesterol* 480~ Cholesterol* 480'1 
IgG* 1000' IgG* . 1000' 
ox-LDL Ab* 60' ox-LDL Ab* 60~ 
Wash-out Cholesterol* 366 ± 40 Cholesterol* 443 ± 97 
IgG* <18 IgG* <18 
ox-LOL Ab* 12.3 ± 1.3 ox-LOL Ab* 24.9 ± -0.5 
Final eluate Cholesterol* 2.9 ±2.3 Cholesterol* 0.2 ± 0.3 
IgG* 768 ± 51 IgG* 797 ± 110 
ox-LDL Ab* 127 ± 61 ox-LDL Ab* 131 ± 41 
a Wash-out with 20 mM sodium phosphate buffer, pH 7.0 followed by elution with 
0.2M glycine-Hel, pH 2.5 
b Wash with 0.1 M NaHC03 pH 8.3 + O.5M NaCI, followed by elution with 0.2M 
glycine-HCI, pH 2.5. 
* All values are means, expressed in micrograms ± SO (n=4) 
1T Concentrations measured in the original precipitate 
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Figure 11. OxLDL antibody levels in serum and polyethylene glycol-precipitated 
immune complexes of type 1 diabetic subjects (N=47 paired serum and PEG-Ie 
samples). OxLDL antibody levels were determined by competitive enzyme 
immunoassay in serum and in IgG purified from polyethylene glycol-precipitated 
immune complexes using protein G chromatography. The assays were 
calibrated with serial dilutions of serum with known concentration of oxLDL 
antibody and calculated in mg/L. The data in the graph is expressed as mean ± 
SEM. Statistical analysis was performed using a paired t-test of oxidized LDL 
antibody concentrations in serum against concentrations of the same antibodies 
isolated from immune complexes. 
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We then investigated whether or not the avidity of oxLDL antibodies isolated 
from sera was comparable in the three subgroups of subjects studied and 
whether or not it would differ from the avidity of oxLDL antibodies contained in . 
immune complexes. As shown in table 6 the Kd values of oxLDL antibodies 
isolated from patient's sera were virtually undistinguishable. A comparison of Kd 
values from serum antibodies and antibodies present in immune complexes 
showed the later to be of higher avidity (serum antibody Kd = 1.13±O.13 07 x 10-8 
mol/L; immune complex antibody Kd = 0.86+0.06 x 10-8 mol/L mol/L; p<0.05). 
The average Kd of IgG antibodies isolated from PEG-precipitated Ie from 
patients with UAE equal or greater than 30 mg/24 hr (microalbuminuric and 
macroalbuminuric) was lower than the average Kd of IgG antibodies isolated 
from PEG-precipitated Ie from patients with UAE below 30 mg/24 hr 
(normoalbuminuric). The differences between the Kd values measured in the 
three different groups did not reach statistical significance, but a statistically 
significant difference (p<O.05) was observed when the Kd values of the patients 
with normoalbuminria were compared with those from a combined group, 
including all patients with abnormal albuminuria (Figure 12). 
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Table 6. Kd values measured in oxLDL antibodies isolated from serum and IgG 
isolated from PEG-precipitated immune complexes 
Variable Patient Groups N Mean SE p p* 
Serum oxLDL Macroalbuminuric 14 1.58 0.24 ns ns 
Antibodies Kd Microalbuminuric 11 1.48 0.27 ns ns 
(10-8 mol/L) Normoalbuminuric 22 1.51 0.19 Reference Reference 
Immune Macroalbuminuric 14 0.87 0.11 ns ns 
Complex Microalbuminuric 11 0.84 0.12 ns ns 
oxlDl Normoalbuminuric 22 1.13 0.08 Reference Reference 
Antibodies Kd 
{10-8 molll) 
*p is adjusted for gender, age, and HbA1c. 
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Figure 12. OxLDL antibody Kd values measured in IgG fractipns purified from 
PEG-precipitated Ie obtained from the sera of type 1 diabetics with UAE under 
30 mg/24 hr (n=22) and equal or greater than 30 mg/24 hr (n=25). IgG was 
purified from polyethylene glycol-precipitated immune complexes using protein G 
chromatography, and Kd levels were determined by competitive ELISA (see 
methods). Results are expressed in 10-8 moles per liter. Statistical analysis was 
performed using analysis of covariance while adjusted for gender, age, and 
HbA1c. 
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Part 2: Discussion 
In spite of the prevalence of nephropathy in type 1 diabetes and its associated 
morbidity and mortality, the pathogenic mechanisms responsible for its 
development· are still poorly understood. However, there'is substantial data 
suggesting that the development of nephropathy in type 1 diabetes mimics, from 
a pathogenic point of view, that of systemic atherosclerosis (Diamond, 1991; Gin 
et aI., 2000; Kamanna et al., 1997; Moorhead et aI., 1997), and that lipids such 
as oxLDL are major contributors to the deterioration of renal function (AI-Shebeb 
et aI., 1988; Bosmans et aI., 2001; Gin et aI., 2000; Lee and Kim, 1998). The 
pathogenic mechanism proposed to explain how hyperlipidemia leads to 
nephropathy involves the infiltration of LDL, due to increased capillary 
permeability,. into the glomerular mesangium followed by LDL oxidation by 
mesangial cells (Wheeler et aI., 1994). As a consequence, there is recruitment 
and accumulation of macrophages (Jeng et aI., 1993; Kamanna et aI., 1999; 
Kamanna et aI., 1996; Suzuki et ai., 2001), phagocytosis of the oxLDL, and 
transformation of these cells into lipid-laden foam cells-a hallmark of diabetic 
nephropathy (Magil, 1999). Ultimately, these macrophages become activated, 
exacerbating the progression of nephropathy through the release of cytokines, 
followed by proliferation of mesangial cells and expansion of the glomerular 
extracellular matrix (Moorhead et aI., 1997; Schreiner, 1991; Shiozawa, 2000). 
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In contrast to nephropathy, the pathogenic role of modified lipoproteins in 
atherosclerosis is well established. It has been investigated from two different 
angles: the direct pro-atherogenic effect of oxLDL (Diamond, 1991; Lopes-Virella 
and Virella, 1998; Witztum, 1994b) and the effect of the immune complexes 
formed as a consequence of the immune response directed against neoepitopes 
resulting from lipoprotein modification (Lopes-Virella and Virella, 1998; Lopes-
Virella et aI., 1999). The development of accurate assays for free oxLDL 
antibodies (Koskinen et aI., 1998; Lopes-Virella'et aI., 2000; Mironova et aI., 
1997) and design and implementation of techniques for the isolation of oxLDL 
antibodies (Lopes-Virella andVirella, 1994a; Virella et aI., 2000) allowed the 
investigation of the possible connection between oxLDL antibodies and various 
manifestations of atherosclerosis. The majority of isolated oxLDL antibodies 
have been characterized as belonging to the IgG isotype, predominantly of the 
IgG1 and IgG3 subclasses, and are of moderate to low avidity, two to three logs 
lower than the average avidity of polyclonal rabbit anti-apolipoprotein B 
antibodies (Virella et aI., 2000). 
Support for the atherogenic role of oxLDL antibodies was initially found in some 
studies showing a positive correlation between increased Circulating oxLDL 
antibody levels and atherosclerotic vascular disease (Bergmark et aI., 1995; 
Klimov et aI., 1988; Maggi, 1994), as well as in the isolation of oxLDL and its 
corresponding antibodies from atheromatous lesions (Itabe et al., 1994; Palinski 
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and Witztum, 2000; Steinberg et aI., 1989). However, our group, as well as 
others, has obtained negative data in studies examining the correlation between 
circulating oxLDL antibody concentrations and atherosclerosis (Hulthe et aI., 
1998; Virella et al., 1993). Even more perplexing are the reports showing that 
the serum concentrations of antibodies to oxLDL are lower in people with 
diabetes-related complications than in those without (Festa et aI., 1998; Orchard 
et aI., 1990). Palinski et al. raised further questions concerning the pathogenic 
role of oxLDL antibodies with a study suggesting that immunization of LDL 
receptor deficient rabbits with homologous MDA-LDL had a protective effect 
relative to atherogenesis (Palinski et aI., 1995). George et al. (George et aI., 
1998) reported similar observations after immunizing apo-E deficient mice with 
MDA-LDL. These observations have been taken out of context to imply that 
humoral immunity to oxLDL has general protective effects in humans (Wick and 
Xu, 1999); ignoring species differences; that the laboratory animals used in these 
experiments were genetically altered; that the titers of antibodies resulting from 
deliberate immunization were considerably higher that those measured in non-
immunized animals; and that no attempt was made to compare IgG subclass 
distribution or avidity values between spontaneous and elicited antibodies. Also 
ignored was the fact that later studies comparing the effects of immunization of 
LDL receptor deficient mice with MDA-LDL and native LDL demonstrated that 
the protective effect of immunization was unrelated to the production of oxLDL 
antibodies (Freigang et aI., 1998). 
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While the pathogenic significance of circulating oxLDL antibodies is 
questionable, as demonstrated by the contradictory results mentioned above, we 
have concentrated our efforts in studying the possible pathogenic role of LDL-
containing IC. The putative role of oxLDL-IC in atherosclerosis is supported by 
both in vivo and in vitro data. In vivo, oxLDL and antibodies reacting with 
modified lipoprotein particles are known to be components of atherosclerotic 
plaques, each having been identified and purified from such lesions, as 
mentioned earlier (Palinski and Witztum, 2000; Steinberg et aI., 1989). In vitro 
experiments demonstrated that LDL-IC interact with the high avidity Fc receptor 
(FerRI) of monocytes and macrophages (Lopes-Virella et aI., 1997a) and are 
extremely potent activators of human macrophages, leading to cholesterol ester 
accumulation, unregulated expression of LDL receptors, and release of pro-
inflammatory cytokines, metalloproteinases and reactive oxygen species (Griffith 
et aI., 1988; Huang et aI., 1999; Kiener et aI., 1995; Klimov et aI., 1988; Tertovet 
aI., 1990b; Virella et aI., 1995). This was the impetus for re-examining the 
question of the pathogenic role of Ie in atherosclerosis, focusing specifically on 
LDL-containing Ie. 
Tertovet al. proposed in 1990 that LDL-containing Ie played a pathogenic role in 
atherosclerosis based on in vitro data demonstrating that cholesterol-rich PEG 
preCipitates had atherogenic properties when incubated with human 
macrophages (Tertov et aI., 1990a). This led the same group to propose that 
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LDL-IC could be used as markers of atherosclerosis (Orekhov et aI., 1991 a). 
Later publications on the same topic had conflicting conclusions. Boullier et aI., 
using an enzyme immunoassay for LDL-IC detection, reported that LDL-IC were 
not increased in subjects suffering from coronary atherosclerosis (Boullier et aI., 
1995). In contrast,- Ahmed et aI., using a similar assay, reported a higher 
prevalence of circulating IC in diabetic patients with vascular complications 
(Ahmed et aI., 1999). Our initial studies failed to clarify the issue, when we 
proved that atherogenic Ie could be isolated not only from the sera of subjects 
with diabetes, but also from the sera of normal controls (Mironova et aI., 1997). 
However, data from a prospective study of a group of type I diabetic subjects 
demonstrated that LDL-IC were risk factors for coronary heart disease in these 
patients (Lopes-Virella et aI., 1999; Orchard et aI., 1999). 
A suspected correlation between ox LDL antibodies and diabetic nephropathy 
was first investigated by Korpinen et aI., but they found no association between 
serum levels of oxLDL antibodies and diabetic nephropathy or nephropathy-
related macroangiopathy (Korpinen et aI., 1997). In our current study we were 
also unable to show a significant correlation between free, circulating oxLDL 
antibody levels and proteinuria. However, when we focused our attention in 
LDL-IC levels we obtained evidence supporting the involvement of LDL-IC as 
pathogenic factors in diabetic nephropathy, as reflected by abnormal 
albuminuria. Significantly higher levels of cholesterol and apolipoprotein B were 
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detected in the PEG precipitates of subjects with abnormal UAE, particularly 
those with macr9albuminuria.But more significantly, we were able to purify 
antigen-free IgG from PEG precipitates and demonstrate that it contained oxLDL 
antibodies, and that these antibodies were of higher avidity than free, circulating 
oxLDL antibodies. Furthermore, we have shown that the avidity of antibodies 
contained in PEG precipitates was significantly higher in subjects with abnormal 
UAE values. The nature of the LDL molecules found in the PEG precipitates 
could not be established directly by the performed assays of cholesterol and 
Apo-B. No fully satisfactory. method for specific assay of oxLDL in small 
samples, such as PEG precipitates, is available. Attempts to develop 
immunoassays have not been successful because of the lack of adequate 
commercially available polyclonal or monoclonal antibodies. Chemical assays, 
on the other hand, require considerable quantities of lipoprotein that cannot be 
obtained from clinical samples. However, the demonstration of oxLDL antibodies 
in the PEG precipitates strongly supports the hypothesis that the PEG-
precipitable IC contain oxLDL. 
This, to our knowledge, is the first report showing evidence that supports a 
pathogenic role for oxLDL-containing Ie in diabetic nephropathy.. Our data 
further suggest that the pathogenic potential of oxLDL IC is directly related to 
oxLDL antibody avidity .. The correlation between antibody pathogenicity and 
avidity agrees with classical observations published by Winfield et al. who 
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demonstrated in the late 1970s that ,the avidity of antibodies eluted from 
deposited Ie was significantly higher than the avidity of circulating antibodies of 
the same specificity (Winfield et aI., 1977). The fact that Ie containing IgG 
oxLDL antibodies of higher avidity predominated in patients with micro and 
macroalbuminuria is likely to be a reflection of the fact that as the antibody 
avidity increases, the ability to form stable complexes is enhanced~ The 
formation of stable IC involving biologically active antibodies (lgG1 and IgG3 
particularly) is, in turn, a requirement for the activation of pro-inflammatory 
mechanisms (Theofilopoulos and Dixon, 1979). From previous work conducted 
in our laboratory we know that oxLDL antibodies are predominantly of the IgG1 
and IgG3 isotypes (Mironova et aI., 1996), able to activate the classical pathway 
of the complement system and to engage all known types-of Fey receptors 
(Virella and Wang, 1998). 
The process by which oxLDL-IC mediate glomerular damage is not clear. 
OxLDL has been shown to induce proliferation of mesangial cells, a prominent 
feature of diabetic nephropathy (Moorhead et aI., 1997), and cause the 
expansion of the extracellular matrix (Diamond, 1991; French et al., 1967). In 
tum, mesangial cells have been shown to oxidize LDL (Wheeler et at, 1994). In 
the case of human macrophages, the higher atherogenic potential of ox-LDL Ie 
relative to free oxLDL seems to be related to the engagement of FcyRI by the Ie 
(Lopes-VirelJa et aI., 1997a). Human mesangial cells have been reported to 
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express this same receptor after activation by interferon-y (Uciechowski et aI., 
1998) .. It remains to be determined if uptake of oxLDL Ie through this receptor 
can activate mesangial cells to the same extent as macrophages. If it does, the 
question of the in vivo cellular source of interferon-y will arise. As in the 
pathogenesis of large vessel atherosclerosis, it is likely that a variety of immune 
cells·are involved in the process. Activated T cells reacting with oxLDL and hsp-
50-derived epitopes have been detected in atheromatous lesions (Stemme et aI., 
1995). A similar involvement at the glomerular level could account for the 
release of interferon-y and mesangial cell activation. These and many other 
questions will have to be explored to reach a better understanding of the 
pathogenic role of oxLDL-IC in diabetic nephropathy. 
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Part 3: Effects of Homologous Human OxLDL·Containing Immune 
Complexes Ie on Human Macrophage-like Cell Line, THP-1 Cells 
Part 3: Introduction 
During the last 20 years, research in cardiovascular disease has accumulated a 
large body of evidence suggesting an important role for low density lipoprotein-
containing immune complexes (LDL-IC) in the pathogenesis of atherosclerosis, 
as reviewed by Lopes-Virella and Virella in 1998 (Lopes-Virella and Virella, 
1998). Supporting the proatherogenic role of LDL-IC are reported observations 
that atherosclerotic lesions contain both oxLDL and LDL antibodies (Itabe et at, 
1994; Palinski and Witztum, 2000; Steinberg et al., 1989; Steinbrecher et aI., 
1990). Epidemiological data has been obtained suggesting that soluble LDL-IC 
are detected in the serum of subjects with coronary artery disease (CAD) at 
levels significantly higher than subjects without CAD (Lopes-Virella et aI., 1999; 
Orchard et aI., 1999; Orekhov et aI., 1991a; Tertov et ai., 1990a), with data 
obtained' in a 'prospective study involving diabetic subjects suggesting that 
increased levels of LDL-IC were predictive of CAD (Lopes-Virella et at, 1999; 
Orchard et aI., 1999). Additionally, soluble LDL-IC isolated from the serum of 
subjects with coronary heart disease, by chromatography using immobilized 
staphylococcal protein A or precipitation with polyethylene glycol, have been 
shown to be atherogenic, as indicated by their ability to induce intracellular 
accumulation of cholesterol and cholesteryl ester (CE) in pericardial 
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macrophages and smooth muscle cells (Klimov et aI., 1988; Tertov et aI., 
1990a). 
Transformation of human monocyte-derived macro phages into lipid-laden foam 
cells is a key manifestation of the atherosclerosis process (Gerrity, 1981; 
Schaffner et aI., 1980). Therefore, it should come as no surprise that the role of 
LDL-IC in foam cell formation has received significant attention. Beginning in the 
1980s, researchers in our group began investigating the effects of LDL-IC on 
human monocyte-derived macrophages, and later on, we extended these 
observations to the human monocytic cell line THP-1 , a widely used human 
macrophage model (Auwerx, 1991; Lopes-Virella et aI., 1997a). Numerous 
studies in our laboratory have shown that co-incubation of human monocyte-
derived macrophages with LDL-IC prepared with human native LDL and rabbit 
anti-human LDL antibodies cause intracellular CE accumulation, and subsequent 
foam cell formation more efficiently than any other known mechanism of foam 
cell formation (Griffith et ai., 1988; Lopes-Virella et aI., 1991). The massive 
intracellular increase in cholesterol and CE accumulation and impaired 
cholesterol homeostasis observed in THP-1 cells incubated with LDL-IC mirror 
the effects of LDL-IC on human monocyte-derived macrophages, substantiating 
the use of this cell line as a model of human monocyte-derived macrophages 
(Huang et aI., 1997). 
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Substantial data has been accumulated, suggesting that the intracellular 
accumulation of cholesterol and CE in macrophages incubated with LDL-IC, and 
resultant foam cell formation, is the result of a complex series of actions 
triggered by LDL-IC. For example, the results of studies conducted in our 
laboratory indicate that the massive CE accumulation is due to a combination of 
increased uptake and impaired intracellular metabolism of the ingested LDL 
component of the LDL-IC (Lopes-VirelJa et aI., 1991). We have demonstrated 
that the amount of LDL taken up by human macrophages at the end of 5 hours is 
an impressive 7-fold higher when the LDL is complexed with antibody than when 
cells are incubated with native LDL alone. In addition to enhanced ingestion of 
LDL-IC, we have also observed that there is a delay in degradation of LDL when 
it is complexed with IgG. Pulse-chase experiments have shown that degradation 
of IC-complexed LDL takes up to 48 hours, and that as the LDL is hydrolyzed; 
cholesterol is released and re-esterified by ACAT leading to intracellular 
cholesterol and CE accumulation (Lopes-Virella et aI., 1991). Taken together, 
these observations demonstrate the ability of LDL-IC to cause intracellular lipid 
accumulation by at least two mechanisms: increased lipid ingestion, and 
decreased lipid clearance. 
Thus, there is solid evidence suggesting a role for LDL-IC in the pathogenesis of 
atherosclerosis. Unfortunately, the vast majority of these studies have been 
performed using LDL-IC prepared with human LDL and rabbit hyper-immune 
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anti-sera against human LDL, or an ill-defined heterogeneous mix of human 
LDL-containing Ie and other Ie isolated from,human sera by PEG precipitation. 
The experimental designs have left unresolved the question of whether LDL-IC 
prepared with heterologous antibodies of much higher avidity than the naturally 
occurring human antibodies truly represent the effect of homologous LDL-IC on 
human macrophages. There is also some uncertainty regarding what types of 
LDL-IC isolated from human serum are responsible for foam cell formation in 
macrophages. In this paper, we report the results of a series of experiments 
supporting our contention that homologous LDL-IC prepared with human oxLDL 
and human antibodies to oxLDL (oxLDL-IC) are metabolized by human 
macrophages similarly to heterologous LDL-IC prepared with human LDL and 
hyperimmune rabbit anti-human LDL serum. We believe that these data prove 
that human oxLDL autoantibodies can form atherogenic LDL-IC and validates 
the continued use of LDL-IC prepared with human LDL and heterologous anti-
LDL antibodies to study the interactions of human monocyte-derived 
macro phages and LDL-IC. 
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Part 3: Results 
The protocol developed for preparing and isolating homologous human oxLDL-IC 
involved multiple steps. We began by isolating oxLDL antibodies from human 
sera, using a column containing oxLDL cross-linked to Sepharose. The eluted 
antibodies were then dialyzed and incubated overnight at 4°C with varying 
concentrations of copper-oxidized LDL to allow formation of oxLDL-IC. Unlike 
the insolu~le immune complexes formed with heterogeneous mixtures of human 
LDL and LDL-hyperimmune rabbit sera, which are relatively simple to make and 
purify, oxLDL-IC formed with human oxLDL and purified human oxLDL 
antibodies are soluble complexes, and cannot be isolated by simple 
centrifugation. To overcome this obstacle, we first prepared soluble oxLDL-IC by 
incubating oxLDL with purified human oxLDL antibodies overnight at 4°C. We 
then added polyethylene glycol (PEG), at a final concentration of 4%, to the 
antigen-antibody mixture to preCipitate the soluble immune complexes. After 
overnight incubation at 4°C, we obtained oxLDL-IC precipitates that were 
isolated by centrifugation, reconstituted in PBS, and subsequently analyzed. 
Figure 13 shows the results of a precipitation curve prepared with different 
antigen-antibody ratios and identical PEG concentrations (4%). The curve 
indicates that optimal yields of oxLDL-IC complexes are obtained when 150 I1g 
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Figure 13. Homologous human oxLDL-IC precipitation curve. 
Variable concentrations of oxLDL isolated from human serum were 
added to 1 mL of purified human oxLDL antibody aliquots 
containing 400f,lg/mL of protein. After overnight incubation, 
addition of 40/0 PEG, and a second overnight incubation, 
precipitates were separated by centrifugation, and protein 
concentration was determined in resuspended precipitates by the 
Lowry method (Lowry et aI., 1951). 
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In order to rule out nonspecific precipitation of proteins by PEG, we next 
designed an experiment to compare the protein concentrations precipitated from 
oxLDL alone, oxLDL + an irrelevant antibody (rabbit anti-Rho), oxLDL + human 
oxLDL antibody, and oxLDL + LDL-hyperimmune rabbit antibody_ In this 
experiment, oxLDL alone and oxLDL + the irrelevant antibody served as negative 
controls, while oxLDL + LDL-hyperimmune rabbit antibody served as a positive 
control. In all conditions, both theoxLDL concentration and antibody 
concentration were kept constant, at 150 Jl9/mL and 400 Jlg/mL, respectively, as 
determined by the Lowry method. The results are graphically represented in 
figure 14, and demonstrate that oxLDL-IC are formed when oxLDL is mixed with 
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Figure 14. Specificity of oxLDL-IC precipitation by 4% PEG. Copper-
oxidized LDL alone, oxLDL plus anti-Rho '(irrelevant) antibodies, oxLDL plus 
purified human oxLDL antibodies, and oxLDL plus purified hyperimmune 
rabbit IgG was precipitated with 4% PEG, and precipitate concentrations 
were compared by protein Lowry. All conditions used a final volume of 1 mL 
in PBS, 150Jlg oxLDL, and 400 fJ.9 of the antibody indicated. 
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Having successfully established a method to reproducibly prepare and purify 
homologous human oxLDL-IC, we then carried out experiments to determine if 
these complexes would alter cholesterol metabolism, resulting in cholesterol and 
cholesteryl ester accumulation in macrophages, as· has been observed in 
macrophages incubated with LDL-IC prepared with human LDL and 
hyperimmune rabbit anti-human LDL antibodies. To this end, we transformed 
monocytic THP-1 cells to macro phages by treatment with 160 nmollL phorbol12-
myristate 13-acetate (PMA) for 3 days, and incubated the THP-1 macrophage-
like cells with varying concentrations of human homologous oxLDL-IC or oxLDL 
alone. During incubation of these macrophages with free oxLDL or with oxLDL-
IC, it was found that the majority of concentrations studied (50-200 mg 
oxLDL/oxLDL-IC per mL) caused an increase in total cholesterol (Figure 15A). 
And we observed that the increase in both components of total cholesterol (free 
cholesterol and eE) was much more pronounced in cells incubated with oxLDL-
Ie, compared to those incubated with free oxLDL (Figure 15A). Beginning at 50 
Jlg/mL, intracellular CE accumulation in cells incubated with oxLDL-IC was 
increased more than 2-fold higher than cells incubated with free oxLDL alone. 
Figure 158, shows that the accumulation of intracellular CE occurred in a dose-
dependent manner, indicating the ability of oxLDL-IC to dramatically alter 
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Figure 15. Cholesterol accumulation in THP-1 cells incubated with variable 
concentrations of oxLDL (OX) and oxLDL-IC (IC). Each point represents the 
average of three experiments performed in duplicate or triplicate. Cells were 
incubated with 0-200 J.lg/mL oxLDL or oxLDL-IC for 48 hours, and cholesterol 
concentrations were determined by GC. 
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During incubation of macrophages with 100 ,....g/mL of oxLDL or oxLDL-IC 
prepared with either human oxLDL antibodies or rabbit anti-human LDL-
hyperimmune serum (Figure 16), we observed.an increase in intracellular 
cholesterol accumulation in cells incubated with free or complexed oxLDL, 
supporting the atherogenic potential of oxLDL. Although oxLDL alone is capable 
of causing foam cell formation, as attested by the 2-fold increase in intracellular 
total cholesterol and 8-fold increase in CE, these data indicate a more profound 
enhancement in intracellular cholesterol accumulation in macro phages incubated 
with oxLDL-IC. Cells incubated with homologous oxLDL-IC prepared with 
purified human oxLDL antibodies and oxLDL nearly doubled the intracellular 
cholesterol levels observed in those incubated with oxLDL alone, and showed a 
3-fold increase in CE, closely approaching the lipid accumulation observed in 
cells incubated with heterologous oxLDL-IC prepared with anti-human LDL-
hyperimmune rabbit serum and oxLDL. Taken together, these data strongly 
suggest that oxLDL-IC prepared with human oxLDL antibodies produce similar 
results to those observed when using heterologous LDL-IC prepared with LDL-
hyperimmune rabbit serum. More importantly, we have shown for the first time 
that the oxLDL-IC likely to be encountered in humans are have more atherogenic 
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Figure 16. Cholesterol mass (J..Ig/mg cell protein) in THP-1 cells incubated with 
for 48 hours with SFM (n=16), 1 00 ~g oxLDL (n=10), 100 IJg human oxLDL-IC 
(H-IC) (n=28), or 100 J,Jg rabbit oxLDL-IC (R-IC) (n=12), that had been 
precipitated by incubation with 4% PEG (18 hr, 4°C). The results are expressed 
as mean of 4-7 experiments with samples run in duplicate or triplicate in each 
experiment. 
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Part 3: Conclusions 
It is well known that the accumulation of CE in macrophages, and subsequent 
transformation into foam cells, is enhanced by incubation of these cells with 
modified forms of LDL (Brown et aI., 1980) and that incubation of macrophages 
with heterologous LDL-IC prepared with human LDL and anti-human LDL-
hyperimmune rabbit sera drives intracellular CE accumulation more efficiently 
than incubation with modified LDL ·alone (Griffith-et aI., 1988; Lopes-VirelJa et aI., 
1997a; Lopes-VirelJa et aI., 1997b; Virella et aI., 1995). Furthermore, Klimovet 
al. (Klimov et aI., 1988) demonstrated that lipoprotein-antibody autoimmune 
complexes isolated from human serum using sucrose density gradient 
ultracentrifugation induced an approximate 3-fold CE increase in murine 
macrophages when compared to the same cells incubated with lipoprotein alone. 
Concurrently with the work of Klimov, data from our group strongly implicated the 
participation of Fc-y receptors in LDL-IC uptake by macrophages by 
demonstrating decreased CE accumulation in cells whose Fc-y receptors were 
blocked (Griffith et aI., 1988), and we later proved that the receptors primarily 
involved in this process were FcyRI (Lopes-VirelJa et aI., 1997a). Unfortunately, 
these studies, though they convincingly showed ·that LDL-IC lead to CE 
accumulation in macrophages, could be criticized by the fact that some authors 
used macrophages isolated from non-human sources (Klimov et aI., 1988), while 
others used LDL-IC prepared with LDL antibodies from a different species 
(Griffith et aI., 1988; Lopes-Virella et aI., 1997a), or used human LDL-IC ·whose 
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constituent components were not well.defined (Klimov et aI., 1988). Some of the 
problems presented by these design flaws are obvious, while others are less 
obvious .. First, with regard to the type of,macrophages used, non-human 
macrophages may, or may not accurately reflect their human counterpart. 
Though these cell lines are cultivated more easily than native human monocyte-
derived macrophages, there may well be species to species differences, 
therefore, human macrophages are obviously preferred. Second, using 
heterologous LDL-IC prepared with LDL-hyperimmune rabbit sera and human 
LDL may be problematic. Since rabbit antibodies are of higher avidity than 
human LDL antibodies (Mironova et aI., 1996) and recognize a wider range of 
epitopes on LOL, they form insoluble LDL-IC. Since the corresponding 
homologous LDL-IC are soluble, one cannot be sure that macrophages 
incubated with these heterologous LDL-IC complexes react Similarly to those 
incubated with homologous LDL-IC. Third, data produced showing CE 
accumulation in macrophages incubated with LDL-IC isolated from human sera 
(Klimov et ai., 1988) are difficult to interpret because the type of antigen involved, 
as well as the antibodies involved in the formation of these complexes is 
unknown. These studies inadequately answer the question of what type of LDL 
modification (glycation, oxidation, advanced glycated end products, etc.) drives 
antibody formation and, therefore, fail to identify and/or characterize the type of 
LOL-IC involved. Finally, the use of native LDL as a negative control may not be 
the best choice as a baseline measurement for several reasons. It is common 
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knowledge that LDL becomes atherogenic only after it is modified (Steinberg and 
Witztum, 1999), that this modification confers immunogenicity (Steinbrecher et 
aI., 1984a), and that LDL-IC are much more efficient than native LDL in their 
abilityto cause foam cell formation in macrophages (Griffith et at, 1988; Klimov 
et aI., 1988; Lopes-Virella and Virella, 1998). Since native LDL is not 
immunogenic, and does not participate in formation of immune complexes, it 
seems reasona.ble to suggest that a modified form of LDL known to participate in 
formation of LDL-IC is a better control in these experiments. 
In the present study, we are the first to report the successful in vitro production 
and purification of human homologous oxLDL-IC, using oxLDL and oxLDL 
antibodies isolated from human serum (Figure 14). OxLDL was chosen as the 
antigen for this group of experiments because it occurs in vivo and has been 
observed in foam cells and atherosclerotic plaques (ltabe et aI., 1994; Lee and 
Kim, 1998; Magil, 1999; Palinski et aI., 1995; Palinski and Witztum, 2000; 
Steinberg et aI., 1989). We then embarked on a series of experiments aimed at 
overcoming the afore mentioned potential problems encountered by using 
heterologous LDL-IC by using human monocyte-derived THP-1 macrophages 
incubated with homologous oxLDL-IC, and used oxLDL as our baseline control, 
rather than native LDL alone. We observed an accumulation of cholesterol 
esters when human monocyte-derived THP-1 macro phages were incubated with 
homologous oxLDL-IC that approached levels observed in macrophages 
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incubated with oxLDL-IC prepared with anti-human LDL-hyperimmune rabbit 
sera (Figure 16). Furthermore, this accumulation of cholesterol esters was 
consistently higher than that observed in macrophages incubated with oxLDL 
alone (Figure 15), with cholesterol ester concentrations ranging from 3 to 6-fold 
higher than those observed in cells incubated with oxLDL alone. 
In summary, these data provide conclusive evidence that homologous oxLDL-IC 
prepared with human oxLDL and purified human oxLDL antibodies are actively 
ingested by macrophages. Moreover, when homologous oxLDL-IC are 
incubated with human monocyte-derived THP-1 macrophages, they appear to 
result in transformation of these cells into foam cells, approaching the efficiency 
observed in earlier studies where macro phages were incubated with 
heterologous LDL-IC (Gisinger and Lopes-Virella, 1992; Griffith et aI., 1988; 
Klimov et aI., 1985; Lopes-Virella at aI., 1997b). Together, these data 
demonstrate that homologous oxLDL-ICnot only cause cholesterol and 
cholesteryl ester accumulation in macrophages, but also are significantly more 
efficient in their atherogenic potential than oxLDL alone. These observations 
support the hypothesis presented by Lopes-Virella et al. that oxidized LDL-
containing immune complexes (oxLDL-IC) are active participants in foam cell 
formation and atherosclerosis (Lopes-Virella and Virella, 1998). Moreover, these 
data support the continued use of heterologous LDL-IC, prepared with human 
LDL and LDL-hyperimmune rabbit serum, in studies of the effects of LDL-IC on 
human monocyte-derived macrophages, foam cell formation, and atherogenesis. 
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Chapter V 
Summary and Conclusions 
Patients with diabetes mellitus tend to develop a multitude of microvascular and 
macrovascular complications, with heart disease" being the number one cause of 
death in diabetes (Breyer, 1992; CDC, 1999; Cooper et aI., 1997; Kamanna et 
aI., 1997; Lloyd etal., 1996; Maseretal., 1991; Nathan, 1993; NCHS/CDC, 
2000; Orchardet aI., 1990). Accruing evidence suggests that two major vascular 
complications of diabetes, nephropathy and atherosclerosis, may share 
pathogenic mechanisms (Figure 17), with nephropathy involving mainly small 
vessels (capillaries, arterioles, and small arteries), while atherosclerosis is 
primarily a disease of large arteries (Diamond, 1991; Hirano, 1999; Kamanna et 
aI., 1997; Moorhead et aI., 1997). Although diabetes is a well-defined risk factor 
for atherosclerosis and nephropathy, the mechanisms responsible for lesion 
pathogenesis in these subjects are multifaceted and have not been totally 
defined. However, given the fact that glycated proteins are commonly formed in 
subjects with diabetes and that glycated proteins are more susceptible to 
oxidation (Mullarkey et ai., 1990; Nathan, 1996; Wolff, 1987), it is not surprising 
that investigations of the role of modified proteins and lipoproteins in vascular 
disease pathogenesis have been intense. Two key participants in 
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atherosclerosis and nephropathy that have received considerable attention are 
oxLDL and foam cells (Itabe et aI., 1994; Kamanna et aI., 1997; Kreisberg, 1998; 
Lopes-Virella and Virella, 1998; Magil, 1999; Palinski and Witztum, 2000; 
Shiozawa, 2000), with the altered metabolism of diabetes believed to be 
responsible for increased oxidant stress and subsequent oxidation of LDL 
(Brownlee et aI., 1984; Cooper et aI., 1997; Hunt et al., 1993; Lopes-Virella and 
Virella, 1998; Mullarkey et aI., 1990; Wolff, 1987). Mechanisms by which oxLDL 
may contribute to atherosclerosis and glomerulosclerosis are numerous. OxLDL 
is chemotactic for monocytes, and is ingested by monocyte-derived 
macrophages via scavenger receptors, bypassing the normal negative feedback 
regulatory loop observed when native LDL is ingested via the LDL receptors. As 
a result, oxLDL leads to foam cell formation, a prominent feature of both 
atherosclerosis and glomerulosclerosis (Diamond, 1991; Lopes-Virella and 
Virella, 1998; Magil, 1999; Parthasarathy et aI., 1986; Steinberg and Witztum, 
1999). 
In addition to the well-demonstrated ability of oxLDL to induce the transformation 
of macro phages into foam cells, it has also been shown to be cytotoxic to 
vascular endothelial cells, thus able to damage the endothelium and contribute 
to the progression of atherosclerosis (Cathcart et aI., 1985; Morel et aI., 1984). 
Macrophages may, in tum, contribute to the oxidation of LDL by generating free 
radicals or through the myeloperoxidase pathway (Heinecke, 1998; Hunt and 
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Wolff, 19911). In addition, macro phages are likely to promote atherosclerosis 
and glomerulosclerosis by secreting various potent cytokines that profoundly 
influence other vascular cells, including endothelial cells and T cells (Hansson, 
1997; Schreiner, 1991; Terkeltaub et aI., 1998). Macrophages further contribute 
to atherosclerotic lesion expansion by secreting transforming growth factor-
~, which causes expansion of the extracellular matrix by upregulating production 
of fibronectin, collagen, and proteoglycan synthesis (Berliner et aI., 1990). In 
both atherosclerosis and glomerulosclerosis, fibrosis probably continues 
independently of the initial stimulus. 
Many groups researching this area have devoted their efforts to dissecting the 
effects of oxLDL in atherogenesis and glomerulosclerosis (Berliner et aI., 1990; 
Diamond, 1991; Guijarro and Keane, 1994; Haberland et aI., 1982; Haberland et 
aI., 1988; Heinecke, 1998; Hirano, 1999; Jeng et aI., 1993; Kamanna et aI., 
1999; Maggi, 1994; Moorhead et aI., 1997), but there is also solid evidence that 
oxLDL is immunogenic, supported by numerous reports of detectable antibodies 
to oxLDL and MDA-LDL (an epitope of oxLDL) in human sera by a variety of 
research groups, including our own (Bellazzi et aI., 1993; Bergmark et aI., 1995; 
Korpinen et aI., 1997; Lopes-Virella et aI., 1999; Maggi, 1994; Salmon et aI., 
1987; Salonen et aI., 1992; Virella et at., 2000; Virella et aI., 1993). Furthermore, 
support for a pathogenic role for LDL autoantibodies comes from the 
observations of researchers showing that LDL-containing Ie prepared in vitro or 
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Figure 17. Analogies of atherosclerosis and glomerulosclerosis. Both 
processes are triggered by endothelial insult, followed by an influx of monocytes. 
The monocytes then transform into lipid-laden macrophages (foam cells), and 
appear to secrete a variety of pro-inflammatory products, thus causing further 
endothelial insult. As the disease progresses, there is smooth muscle cell or 
mesangial cell expansion in atherosclerosis and glomerulosclerosis, respectively, 
along with expansion of the extracellular matrix. Left unimpeded, complications 
arise. (Diamond, 1991; Nathan, 1987). 
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isolated from human serum can induce intracellular accumulation of cholesterol 
esters (Gisinger and Lopes-Virella, 1992; Gisinger et aI., 1991; Griffith et aI., 
1988; Klimovet aI., 1985; Klimov et aI., 1988; Lopes-Virella et aI., 1991; Tertov 
etal., 1990a; Virella et aI., 1995). Our group has pioneered research in this 
area, focusing on the active role of antibodies to modified forms of LDL and the 
LDL-immune complexes (LDL-IC) they form in atherogenesis and diabetes 
(Lopes-Virella et aI., 1996; Lopes-Virella et al.~ 1997b; Lopes-Virella and Virella, 
1998; Virella et aI., 1995). Subsequently, we have convincingly demonstrated 
the atherogenic potential of heterologous oxLDL-IC prepared with human oxLDL 
and anti-human LDL-hyperimmune rabbit serum (Gisinger and Lopes-Virella, 
1992; Gisinger et al., 1991; Griffith et aI., 1988; Lopes-Virella et aI., 1991). Our 
in vitro studies have shown that stimulation of human monocyte-derived 
macrophages with insoluble heterologous LDL-IC led to an unparalleled 
transformation of these cells into foam cells (Griffith et aI., 1988), as well as their 
activation (Virella et aI., 1995). These observations documented that exposure 
of human macrophages to LDL-IC led to increased uptake and impaired 
degradation of LDL (Lopes-Virella et aI., 1991), along with enhancement of a 
variety of cellular functions, including the release of pro-inflammatory cytokines 
such as interleukin-1 ~ and tumor necrosis factor (TNF) (Virella et aI., 1995). 
These activated macrophages can have pathological significance in that the 
secreted cytokines contribute to vascular injury by upregulating the expression of 
adhesion molecules, thus increasing the adherence of leukocytes to the 
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endothelial cells (Lopes-VirelJa et aI., 1982) and promoting their migration into 
the subendothelial space. Further substantiating the activation of macrophages 
by LDL-IC, we demonstrated the ability of LDL-IC to cause respiratory burst in 
human macrophages (Virella et aI., 1995). 
The observations described above strongly suggest that modulation of the 
immune system plays an important role in the pathogenesis of atherosclerosis 
and glomerulosclerosis, and prompted us to further characterize the involvement 
of LDL-IC and macrophages in these processes. Our studies were roughly 
divided into three aims. We sought to 1) characterize of free and immune 
complex-bound oxLDL antibodies; 2) determine if LDL-IC were associated with 
nephropathy, as is the case with atherosclerosis; and 3) determine the 
atherogenicity of homologous oxLDL-IC prepared with human oxLDL and 
purified human anti-oxLDL antibodies. 
The in-depth characterization of human oxLDL antibodies reported in this 
dissertation was a complex process that required the isolation and purification of 
both soluble (free) and immunocomplexed (bound) oxLDL antibodies from 
serum. OxLDL antibodies isolated from both serum and LDL-IC were 
predominantly IgG (primarily subclasses IgG1 and IgG3), followed by IgM and 
minute levels of IgA. These IgG subclasses are known to activate phagocytic 
cells and, the complement system, therefore, their presence in LDL-IC supports a 
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proinflammatory role in atherosclerosis and glomerulosclerosis. We also 
observed that the avidity of oxLDL antibodies isolated from immune complexes 
was significantly higher than the avidity of unbound antibodies of the same 
specificity isolated from serum, suggesting that there is a threshold of antibody 
avidity required for the formation of stable LDL-IC, and that antibodies of oxLDL 
are of sufficiently high avidity to form stable IC. Antibodies of lower avidity 
remain in the circulation and are probably non-pathogenic. Collectively, these 
findings indicate a possible pathogenic role for oxLDL antibodies and the oxLDL-
IC they·help form. These observations, furthermore, indicate that LDL-IC 
formation may help explain the discrepant association of oxLDL antibody levels 
and atherosclerosis/glomerulosclerosis. Indeed, it is reasonable to expect that 
these Ie concentrations may have a stronger correlation with vascular disease 
than that of oxLDL antibody levels alone. 
With regard to the second undertaking of this research project, three 
observations sparked our interest, causing us to investigate if LDL-containing 
immune complexes were associated with diabetic nephropathy. First, our 
literature review revealed that diabetes dramatically increases an individual's risk 
for all types of vascular disease (Cooper et aI., 1997; Nathan, 1993). Although 
there is little doubt that a positive relationship between hyperglycemia and 
microvascular disease exists, hyperglycemia alone is not sufficient to cause the 
observed pathology (Raptis and Viberti, 2001; Wolff, 1987). Second,' it has been 
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successfully argued that glomerulosclerosis, the root cause of diabetic 
nephropathy, is an ~nalogous proce.ss to atherosclerosis (Diamond, 1991; 
Diamond, 1994; Moorhead et aI., 1997); with oxLDL and foam cells actively 
participating in the development of diabetic nephropathy (Jeng et al., 1993; 
Kamanna et aI., 1999; Kamanna et aI., 1996; Magil, 1999; Suzuki et aI., 2001), 
as well as in atherosclerosis (Lopes-Virella and Virella, 1998). Third, an active 
involvement of LDL-IC in atherosclerosis is supported by in vitro observations of 
the conversion of monocyte-derived macrophages into foam cells by LDL-IC, the 
activation and release of proinflammatory cytokines by macrophages incubated 
with LDL-IC, and demonstration of a positive correlation between clinical 
manifestations of atherosclerosis and LDL-IC levels in subjects with diabetes 
(Lopes-Virella et aI., 1997b; Orchard et aI., 1999). 
If atherosclerosis and glomerulosclerosis are indeed analogous processes, and 
LDL-IC are active participants in atherosclerosis, we hypothesized that a similar 
positive correlation would exist between nephropathy and LDL-IC. This was 
indeed the case. When we compared various components of LDL-IC, including 
LDL surrogate-markers such as cholesterol and apolipoprotein B (apoB), along 
with free and Ie-bound oxLDL antibodies in diabetic subjects with varying 
degrees of nephropathy, we made several interesting discoveries. Our analysis 
of PEG-precipitated soluble immune complexes for LDL surrogate markers, 
cholesterol and apoS, showed a positive correlation between urine albumin 
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excretion (an indicator of the severity of nephropathy) and LDL-IC. Additionally, 
we isolated oxLDL antibodies from the PEG-precipitated immune complexes. 
Although PEG precipitates immune complexes irrespective of the 
antigen/antibody composition, the isolation of oxLDL antibodies from Ie that also 
contained apaB and cholesterol firmly established the presence of oxLDL-IC as 
components of these complexes. Lastly, we demonstrated that the avidity of 
oxLDL antibodies isolated from PEG-precipitated immune complexes was higher 
in immune complexes isolated from subjects with advanced nephropathy 
(macroalbuminuria), compared to those with no detectable nephropathy 
(normoalbuminuria), suggesting that the stability of oxLDL-IC may playa role in 
nephropathy. 
Although these findings may be interpreted to suggest that oxLDL-IC actively 
participate in the pathogenesis of both atherosclerosis and glomerulosclerosis, 
we fully realize that mere association does not equal causation. However, data 
obtained in a small cohort of type 1 diabetic subjects (n=98), the Pittsburgh 
Epidemiology Study of Complications, strongly favors a causal effect of LDL-IC 
in atherosclerosis since the elevation of LDL-IC preceded the appearance of 
CHD (Lopes-Virella et aI., 1997b; Orchard et ai., 1999). In fact, the baseline 
levels of LDL-IC obtained at the beginning of the study, when the patients were 
free of macrovascular disease, were significantly higher in the group that 
eventually developed macrovascular complications than in a matched case-
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control grou·p who did not deveJop macrovasculardisease. These data require 
confirmation via large-scale prospective studies of this type, wherein markers of 
LDL .. IC are quantitated in the sera of subjects destined to progress to 
nephropathy, or other measurable indicators of vascular disease. If these 
markers are found to be present at increased levels compared to non-
progressors, the causative role of LDL-IC in the vascular disease of interest will 
be strengthened . 
. Turning to our third goal, we wished to address the issue of whether or not 
. homologous oxLDL-IC, made with human oxLDL and purified human oxLDL 
antibodies, would cause foam cell formation in human monocyte-derived. 
macrophages, as had been observed using LDL-IC made with anti-human LDL-
hyperimmune rabbit serum (Gisinger et aI., 1991; Griffith et aI., 1988; Lopes-
Virella et aI., 1991; Lopes-Virella and Virella, 1998). To accomplish this task, we 
were able to draw upon the expertise within our group in the area of human 
oxLDL antibody isolation (Mironova et aL, 1996; Virella et aI., 2000), and purified 
relatively large quantities of oxLDL antibodies from human serum. Using these 
antibodies, we developed a novel process for synthesizing and purifying human 
homologous oxLDL-IC using a modification of Zubler's classical method of 
soluble immune complex isolation, with 40/0 polyethylene glycol (Zubler et aI., 
1977). Upon isolation of immune complexes, we then co-incubated these 
immune complexes with cells from the human monocyte-derived macrophage-
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like cell line, THP-1, and determined intracellular cholesterol and cholesteryl 
ester accumulation. Our findings showed a massive intracellular accumulation of 
cholesterol and cholesterol esters in THp ... 1 cells incubated with homologous 
human oxLDL-IC that was several fold higher than that of cells incubated with 
oxLDL alone, and approached that of cells incubated with heterologous LDL-IC 
made with hyperimmune rabbit sera. Added to this, parallel experiments carried 
out by Koskinen and others in our group showed increased TNF expression in 
THP-1 cells incubated with human red blood cells that had been coated with 
oxLDL and purified oxLDL antibodies (unpublished data), strongly suggesting 
that these Ie are capable of activating macrophages. These observations 
strengthen the hypothesis that LDL-IC modulate the human immune system in a 
proinflammatory manner, thus demonstrating the potential to exacerbate the 
development -and progression of atherosclerosis (Lopes-Virella and Virella, 1998; 
Lopes-Virella et aI., 1999). These observations are significant on several levels. 
First, and foremost, these findings strongly implicate oxLDL-IC in the 
pathogenesis of atherosclerosis and glomerulosclerosis. Second, these findings 
validate the continued use of heterologous LDL-IC prepared with LDL-
hyperimmune rabbit sera in future studies of this nature. Third, this is the first 
published report describing- preparation of human homologous oxLDL-IC, along 
with its effect on human macro phages. 
As is always the case, much work remains to be done. The mechanisms behind 
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the accelerated development of vascular diseases such as atherosclerosis and 
nephropathy in type 1 diabetes are poorly understood. Therefore, the definition 
of predictors that could lead to the identification "of patients at risk for accelerated 
development of atherosclerosis and/or nephropathy could represent a major 
advancement in the treatment of these patients. If the levels or characteristics of 
LDL-IC are proven to have such predictive power, simpler methods for their 
identification can be developed .. Patients identified by these predictors should 
benefit from treatment with immunomodulators aimed at decreasi~g the 
production of pathogenic LDL-IC. 
Accordingly, the precise nature of the LDL modifications associated with the 
synthesis of antibodies of sufficient avidity as to form stable LDL-IC that may be 
proinflammatory, and thus contribute to both nephropathy and macrovascular 
complications deserves investigation. Quantification of the various types of 
naturally occurring LDL modifications in circulation will require raising antibodies 
to these antigens, and the development of enzyme immunoassays (EIAs). 
These EIAs can then be used to screen retrospectively for these modifications in 
the baseline sera/Ie samples of patients from the DCCT cohort who either 
developed atherosclerosis and/or nephropathy and a matched group of patients 
who remained free of complications.. This data will be used to determine if high 
concentrations of LDL-containing some of these modifications in the baseline 
sera and/or IC are predictive of the development of nephropathy and/or 
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atherosclerosis. Further studies designed are needed to characterize 
immunogenic modifications of LDL (glycation, MDA-Iysine, AGE/ALE) and 
determine if the presence of these modifications predict the development of 
vascular complications are often ob.served in people with diabetes. Similarly, the 
antibodies associated with these modified forms of LDL need to be characterized 
by isotype and avidity to determine if a. specific subset is predictive of future 
glomerulosclerotic or atherosclerotic pathology. The definition of such predictors 
could lead to the identification of patients in which treatment with 
immunomodulatory statins (Chen et aI., 2002) or stronger immunomodulators, 
such as hydroxychloroquine (Wallace, 1996; Wallace et aI., 1993), would prevent 
the development of micro- and macrovascular complications. Lastly, the 
proinflammatory and atherogenic potential of LDL-IC formed between various 
modifications of LDL and their corresponding antibodies needs to be tested in 
vitro by incubating these LDL-IC with macro phages and mesangial cells and then 
determining intracellular cholesterol and cholesterol ester accumulation, as well 
as release of cytokines, specifically TNF, IL 1~, IL6 and GM-CSF. 
In conclusion, diabetes mellitus is a disease associated with serious vascular 
complications. And we have presented data suggesting that oxLDL-IC may play 
a critical role in the pathogenesis of both microvascular and macrovascular 
disease. Specifically, we are the first to report the positive association of oxLDL-
IC and diabetic glomerulosclerosis, and the design of a novel protocol for 
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preparing purified homologous human oxLDL-IC. Additionally, we have reported 
the results of a series of experiments that strongly implicate the ability of these 
complexes to drive macrophage foam-cell transformation, a pathological 
component of both atherosclerosis and glomerulosclerosis. These data form a 
very strong body of evidence implicating oxLDL-IC as a culprit in vascular 
disease, and present, for the first time, proof that IC formed from human oxLDL 
and purified human oxLDL antibodies modulate this process in a negative 
direction more so than oxLDL alone. At this point, these observations represent 
the conceptual framework for on-going investigations that, if fruitful, promise to 
illuminate new perspectives for prevention and intervention of both micro- and 




Diabetes mellitus (DM), is a disorder of glucose metabolism that progressively 
compromises the function of virtually every organ system in the human body 
as its secondary complications inexorably develop (CDC, 1999; Nathan, 1993; 
NCHS/CDC, 2000) (Table 1), and has the notoriety of being the fourth leading 
cause of death by disease in the United States (Table 7). Diabetes is 
characterized by hyperglycemia and affects approximately 15.7 million people 
(or 5.9% of the population) in the United States, with an estimated economic 
cost to our nation recently reaching $98 billion dollars per year (ADA, 1998). 
Two major forms of diabetes, type I diabetes and type II diabetes, are 
distinguished by the need for exogenous replacement of insulin. People with 
type I diabetes, previously termed insulin-dependent diabetes mellitus (100M), 
account for approximately 10% of OM in the United States. This form of 
diabetes usually appears abruptly before the age of 40, with typical symptoms 
of thirst, excessive urination, increased appetite, rapid \",eight loss, and high 
levels of sugar in the urine. In type I diabetes, there is destruction of the 
pancreatic beta-cells in the islets of Langerhans, result!ng in an absolute 
deficiency of the hormone, which necessitates exogenous insulin replacement 
therapy. Type II diabetes, previously known as nO:1-insulin-dependent 
diabetes mellitus (NIDDM), accounts for approxirnately 90% of DM in the 
United States, and usually occurs gradually in peopie over the age of 40 who 
are overweight. It is caused by a quantitative decrease in insulin production or 
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Table 7. -Estimated number of deaths for the 10 leading causes of death: 
United States, 2000 (NCHS/CDC, 2000) 
Total Percentage 
Rank Cause of death number of deaths 
1 Heart disease* 709,894 38.0 
2 Cancer* 551,833 29.6 
3 Stroke 166,028 8.9 
5 Chronic lower respiratory disease* 123,550 6.6 
4 Accidents 93,592 5.0 
6 Diabetes* 68,662 3.7 
7 Pneumoniallnfluenza 67,024 3.6 
8 Alzheimer's Disease 49,044 2.6 
9 Kidney disease* 37,672 2.0 
10 Sel2ticemia 31,613 1.7 
All causes 1 ~898z912 100.0 
*Causes of death due to disease 
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or impaired insulin sensitivity, or a combination of th,:~ t-VV0. l-he majority of 
subjects afflicted with type II diabetes can be mana~E!d vlith diet and exercise 
alone; however, when this approach fails, treatment \hfith oral hypoglycemic 
agents or insulin is indicated (ADA, 2000). 
OM complications. 
Clearly, the quality of life for people with diabetes is diminished as a 
consequence of increased lifetime risk for development of long-term vascular 
complications including both microvascular disease (nephropathy, retinopathy, 
and neuropathy) and macrovascular disease (atherosclerosis, ischaemic heart 
disease, cerebrovascular disease, and peripheral vascular disease) (Breyer, 
1992; Cooper et aI., 1997; Kamanna et aI., 1997; Lloyd et aI., 1996; Lopes-
Virella and Virella, 1998; Maser et aI., 1991; Nathan, 1993; Orchard et aI., 1990; 
Raskin, 1994). These complications mean that patients with diabetes are more 
likely to have heart attacks, strokes, amputations, kidney failure, and blindness 
than the general population; with accelerated and aggressive atherosclerosis 
being the leading cause of morbidity and mortality in diabetes (Rubin et aI., 
1992)(Table 1 & 8). 
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Table 8 •. Complications of diabetes in the United States (CDC, 1999; 
NCHS/CDC, 2000) 
Deaths 
- Diabetes is the cause of an estimated 65,000 deaths among 
Americans and is a contributing cause in another 95,000 deaths 
annually. 
Heart Disease and Stroke 
- People with diabetes have a two to four-fold increase in heart disease 
and are two to six times more likely to have a stroke than people who 
do not have diabetes. 
Kidney Disease 
- Diabetes is the single most common cause of end-stage renal 
disease (ESRD - where a person requires dialysis or a kidney 
transplant to live). 
- Thirty to forty percent of those with diabetes develop ESRD. 
- Currently over one-third of all patients with ESRD have diabetes and 
this number is expected to reach 500/0 if the current rate of increase 
continues. 
Blindness 
- Diabetes is the leading cause of blindness among adults 20 to 74 
years of age. 
Amputations 




Diabetic nephropathy: natural history without pharmacological 
intervention. 
For reasons that remain elusive, a significant percentage, but not all people with 
diabetes develop diabetic nephropathy. Additionally, although the cumulative 
incidence of nephropathy appears to be similar in both type I and type II diabetes 
(Hasslacher et aI., 1989), nephropathy in type I diabetes tends to present in a 
more homologous fashion than that in type II diabetes; therefore, this discussion 
will focus primarily on un-arrested nephropathy in type I diabetes. 
Nephropathy is recognized as one of the most severe metabolic components of 
long-term diabetes (Nathan, 1996), with the lifetime risk of developing 
nephropathy being approximately 30-400/0 for type I diabetes and 25-60% for 
type II diabetes (Hasslacher et aI., 1989; Viberti et ai., 1992). If pharmacological 
intervention with angiotensin-converting enzyme (ACE) inhibitors and 
antihypertensives is not introduced early in the following timeline, all people 
destined to develop diabetic nephropathy are expected to progress to end stage 
renal disease (ESRD) through the various stages illustrated in figure 18 (Breyer, 
1992; Mogensen et aI., 1983). 
Early in the course of diabetes, the vast majority of affected people experience 
functional changes in the kidney, such as hyperfiltration and trace amounts of 
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albumin (referred to as microalbuminuria). If pharmacological intervention is not 
instituted, renal morphological changes occur within the next few years. Seven 
to 15 years after onset of diabetes, patients destined for nephropathy reach the 
next stage, termed "incipient nephropathy." During this period, predictors of 
diabetes-related nephropathy such as hyperfiltration, hypertension (HTN), poor 
glycemic control, and microalbuminuria (urinary albumin excretion of 30-300 
mg/day) occur. Approximately 17 years after the onset of type I diabetes, 
macroalbuminuria (urinary albumin excretion of >300 mg/day) is manifested in 
those 30-40% of type I diabetes patients destined to develop overt diabetic 
nephropathy. Once these levels of albumin excretion are reached, renal function 
inexorably declines, with 50% of patients reaching ESRD within 7 years of onset 
of proteinuria. Ultimately, ESRD requires replacement of renal function using 
dialysis or renal transplant. 
What is common amongst all people with nephropathy is a high rate of 
cardiovascular morbidity and mortality. In fact, myocardial infarction is 
recognized as the leading cause of death in these patients (Degoulet et aI., 
1982; Wheeler, 1996). The mechanisms responsible for the increased 
cardiovascular morbidity and mortality in this group of people remain somewhat 
elusive, but are believed to involve the atherogenic lipid profile that commonly 
accompanies nephropathy. 
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Figure 18. The natural history of nephropathy in type I diabetes without 
pharmacological intervention (Breyer, 1992). 
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Nephropathy and atherogenic lipids 
Nephrotic hyperlipidemia is well documented. In 1860, Virchow first recorded its 
presence in medical literature (Virchow, 1860), with his description of 
degeneration in the kidneys of patients with Bright's disease; later Munk 
introduced the term "lipid nephrosis" (Munk, 1916). In 1936, interstitial and 
arterial "lipidosis" was described in people with diabetes (Kimmelsteil and 
Wilson, 1936) and later, glomerular "lipidosis" was noted in intercapillary lesions 
in diabetes (Wilens et aI., 1951). We now know that the albuminuria associated 
with diabetic nephropathy is positively correlated with an atherogenic lipid profile 
and macrovascular disease (Guijarro and Keane, 1994; Moorhead et aI., 1996; 
Wheeler, 1996). Namely, albuminuria is associated with increasing blood levels 
of total cholesterol, low-density lipoprotein (LOL) cholesterol, apolipoprotein S, 
triglycerides, and reduced levels of high-density lipoprotein (HDL) cholesterol. 
Whether these lipid abnormalities are a cause, a consequence, or an 
epiphenomenona of diabetic nephropathy is unknown. However, it is known that 
as plasma albumin levels decrease due to albuminuria, hepatocytes synthesize 
excess amounts of very low density lipoprotein (VLDL) which is carried in the 
circulation byapolipoprotein B (apo-B) (Moorhead, 1991). Once in the peripheral 
circulation, lipases further reduce the VLDL to LDL. Paradoxically, as 
nephropathy-related LDL synthesis increases there is an accompanying slower 
than normal metabolism of LDL in the peripheral circulation (Warwick et aI., 
1990). The tumover rates of VLDL and LDL are slowed for reasons which 
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include decreased activity of two enzymes, lipoprotein lipase (LPL) and lecithin 
chole~terol acyltransferase (LCAT). The reasons for the decreased enzyme 
activity are unknown, but may be partly due to urinary loss of cofactors (Warwick 
et aI., 1990). Nevertheless, plasma levels of LDL cholesterol are increased, thus 
increasing the risk of cardiovascular disease. 
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Appendix 3. ,. 
Atherosclerosis. 
Atherosclerosis is a multifactorial disease that has the notoriety of being 
responsible for more than 500/0 of all mortality in developed nations, and is well 
recognized as the primary contributor to the pathogenesis of heart attack, stroke, 
and gangrene of the extremities (Ross, 1993). Various risk factors associated 
with the disease are listed in table 9. 
Atherosclerotic lesion formation is characterized by a gradual focal progressive 
accumulation of cells, along with extracellular matrix and lipids in the intima of 
mid-size to large arteries. Danger comes when the resulting lesion either 
occludes the vessel or ruptures, thus triggering vascular occlusion via 
thrombosis. The earliest morphological evidence of disease has been 
appropriately termed the ''fatty streak" due to the accumulation of lipid-laden 
macrophages and T lymphocytes within the innermost layer of the artery wall 
(Faggiotto and Ross, 1984; Gerrity, 1981; Joris et aI., 1983). In 1973, Ross et at 
formally proposed the response-to-injury hypothesis, suggesting that 
atherosclerosis might be precipitated by one or more insults to the endothelial 
lining of mid-size and large arteries (Ross and Glomset, 1973). This hypothesis 
has been modified as more data have become available (Lopes-Virella et aI., 
1997b; Lopes-Virella and Virella, 1998; Ross, 1986; Ross, 1993; Steinberg, 
1993). 
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Table 9. Risk factors associated with atherosclerosis (American-Heart-
Association, 2001) 
Non-Modifiable 










- Poor nutrition 
- Obesity 
Events contributing to the formation .of atherosclerotic lesions, as proposed by 
this hypothesis are as follows (Figure 19): The endothelium is injured. The 
injury may be mechanical, most notably at branch points in the arterial tree due 
to hypertension and/or shear stress; or it may be chemical, caused by oxidized 
low density lipoproteins, for example. Alternatively, the injury may be 
immunological, or due to viral or bacterial infection, or due to the effect of toxins. 
Indeed, the etiology of atherogenic injury is not mutually exclusive and may well 
be a combination of one or more of these insults. Nevertheless, after the initial 
injury there is trapping of lipoproteins and increased adherence of circulating 
monocytes and T lymphocytes to the damaged endothelium, followed by 
migration of the monocytes into the subendothelial space. Once in the arterial 
intima, the monocytes differentiate into macrophages, secrete pro-inflammatory 
cytokines, release oxygen active radicals that contribute to oxidation of 
sequestered lipoproteins, ingest and metabolize modified lipoproteins, and are 
transformed into lipid-laden foam cells. The foam cells, along with smooth 
muscle cells and T lymphocytes are primary components of the lesions 
appropriately described as "fatty streaks". Left uninterrupted, the fatty streak 
expands with alternating layers of smooth muscle cells and lipid-engorged 
macrophages, forming more advanced fibro-fatty lesions, ultimately resulting in 
formation of a fibrous plaque. At some point, perhaps as a consequence of 
excessive release of matrix metalloproteinases by activated macrophages 
(Huang et aI., 1999), the plaque may destabilize and rupture, triggering a 
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thrombogenic episode that can either occlude the vessel or cause progression of 
the atherosclerotic lesion. Foam cell formation is recognized as a key 
component of atherosclerosis and, interestingly, is suspected to play an equally 
important role in nephropathy (Diamond, 1991; Magil, 1999; Moorhead et aI., 
1997). 
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Figure 19. The response to injury hypothesis, adapted from Ross, 1999 (Ross, 
1999) . . Atherosclerotic lesions arise in response to endothelial dysfunction that 
is initiated by an injury to the endothelium. The trapping of lipoproteins follows 
Endothelial injury and migration of monocytes into the subendothelial space, 
where the monocytes transform into lipid engorged macrophages (foam cells), 
establishing the lesion known as a fatty streak. Progression of this lesion results 
in a lipid-rich plaque, which may later become unstable and rupture, triggering 
blood clot formation. 
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